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ACADEMIC ABSTRACT 
 
Lyme disease is the most common vector-borne disease in both the United 
States and Europe; however, its pathogenesis is incompletely understood.  The 
studies described in this thesis aid in the elucidation of mechanisms regulating 
murine Lyme arthritis and may suggest mechanisms by which human Lyme 
disease is mediated.  (1) We found that the chemokine KC is responsible for 
neutrophil recruitment and subsequent development of Lyme arthritis and 
carditis.  This was the first study to describe an immunological regulatory 
mechanism mediating disease susceptibility to murine Lyme disease, as resistant 
mice (B6) produce less KC than susceptible (C3H/HeJ) mice and do not develop 
disease. (2) We found that metabolites produced via the COX-2 pathway are 
important for functional resolution and that resolution is likely mediated via the 
PGE2/EP2 axis. (3) We found that although dietary fish oil substitution leads to a 
global shift in eicosanoid production (from AA/LA-derived eicosanoids to 
EPA/DHA-derived eicosanoids) and promotes anti-inflammatory prostaglandin 
production, disease severity is not altered. (4) We found that eicosanoid 
production throughout the course of autoantibody-drive K/BxN serum-transfer 
arthritis differs significantly from that seen during Lyme arthritis and that patterns 
of eicosanoid expression reflect the severity and kinetics of each type of arthritis.  
These studies aid in understanding the immunological mechanisms regulating 
the occurrence and severity of murine Lyme arthritis. 
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CHAPTER ONE 
INTRODUCTION 
 
“…for I do believe that everyone should know the beautiful deeds of which his or 
her tissues are capable (1).” –Guido Majno, The Healing Hand 
 
I. INFLAMMATION 
A. Acute Inflammation 
 Classically, inflammation is defined as a controlled process by which 
immune mediators are recruited to a site of infection or tissue injury (1, 2).  
Stimulation of pattern recognition receptors (PRR), such as toll-like receptors 
(TLR) and nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLR), by insult or injury leads to the activation of endothelial cells and the 
subsequent release of mediators that recruit leukocytes and vasoactive 
molecules that dilate blood vessels (3, 4).  Leukocytes (mainly neutrophils) exit 
dilated blood vessels and are drawn to the site of infection or injury by 
chemokines (e.g.: KC) and bioactive lipids (e.g.: leukotriene B4, LTB4) produced 
by the activated endothelium.  In an effort to clear infection, neutrophils release 
an array of bioactive molecules [including reactive oxygen species (ROS), 
reactive nitrogen species (RNS), and cytokines] and phagocytose any microbial 
invaders. 
 Neutrophils also produce chemokines that recruit monocytes and 
macrophages (5, 6) to further clear infectious agents as well as remove any dead 
2 
cells (including neutrophils that have undergone apoptosis).  These 
macrophages and monocytes also promote tissue remodeling via the production 
of anti-inflammatory, pro-resolving cytokines, such as transforming growth factor 
beta (TGF-β), and lipids such as lipoxins (e.g.: LXA4), resolvins (e.g.: RvE1), and 
protectins (e.g.: PD1) (7). 
 
B. Chronic Inflammation 
 Inflammation that does not lead to the production of molecules that 
function to induce resolution can become chronic and harmful.  Chronic 
inflammation leads to the continuous production of pro-inflammatory molecules, 
recruitment of leukocytes, release of pro-inflammatory granules, and the inability 
of tissues to heal and have their functions properly restored.  The majority of 
studies chronicling classical pathways of inflammation have been conducted 
using models of infection (8).  This is, for the most part, due to the relatively 
straightforward process of inflammation during an infection in which a trigger 
(pathogen) stimulates inflammation, which leads to the clearance of the trigger.  
Once the trigger has been eliminated in these models, inflammation is no longer 
provoked and tissue remodeling can occur. However, inflammation in the 
pathological sense (chronic inflammation) is less understood due to the fact that 
often times no “trigger” has been identified.   
 Using infectious or transient models of inflammation, however, anti-
inflammatory/pro-resolving molecules have been identified that play active roles 
in halting inflammation and promoting tissue restoration and remodeling (e.g.: 
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lipoxins, resolvins, and protectins) (7, 9-11).  The discovery of these molecules 
and their anti-inflammatory/pro-resolving functions has led to an increased 
understanding of the end processes of inflammatory responses.  Whereas once it 
was believed that the cessation of inflammation (resolution) was due to the 
elimination of a “trigger,” now it is understood that resolution is an active process 
that not only requires elimination of a “trigger” (if one exists), but also production 
of molecules that inhibit pro-inflammatory pathways as well as directly promoting 
tissue healing.   
 In light of this information, it is now understood that chronic inflammation is 
due to a combination of dysregulated pro-inflammatory and pro-resolution 
machinery.  Thus, a paradigm shift in treatment modalities for chronic 
inflammatory disease has occurred.  Whereas, historically, anti-inflammatory 
agents such as anti-tumor necrosis factor (anti-TNF) have been recommended 
for treatment of chronic inflammatory disease (e.g.: rheumatoid arthritis), newer 
modalities focus on inducing pro-resolving pathways.  The importance of this 
paradigm shift is the benefits that arise from not inhibiting normal, regulated 
inflammation.  While chronic inflammation is detrimental, regulated inflammation 
is a very important means of restoring homeostasis to tissues that have 
encountered insult or injury.  Side effects of anti-inflammatory agents, such as 
anti-TNF, include increased risk of infection.  Treatments that target pro-resolving 
pathways would enable normal, regulated inflammation to take place, but would 
put a halt to dysregulated inflammatory responses that have become chronic and 
are causing more harm than good to the patient. 
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 Although increased understanding of pro-resolving pathways has 
identified a new target for the investigation of chronic inflammatory disease, 
these pathways are still relatively poorly understood due to the following: 1) many 
pro-resolving pathways are dependent on functional pro-inflammatory pathways 
(7); 2) many molecules have both pro-inflammatory and pro-resolving functions 
which are concentration, time, or even tissue-dependent (12); and 3) enzymatic 
pathways which produce pro-resolution metabolites also produce pro-
inflammatory metabolites (13). Therefore, an increased understanding of these 
pathways will yield important information regarding therapeutic targets for the 
treatment of chronic inflammatory disease. 
 
II. EICOSANOIDS 
A. Eicosanoid Precursors 
 Eicosanoids are small lipids that contain 20 carbons and are derived from 
the omega-6 (ω-6) fatty acids arachidonic acid (AA) and linoleic acid (LA) and the 
ω-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  
AA, LA, EPA, and DHA are dietary fatty acids stored in the phospholipid bilayer 
of the plasma and nuclear membranes (14, 15).  AA and LA are 20-25-fold more 
prevalent than EPA and DHA in the cell membranes of humans consuming a 
“Western diet,” as they are found in large amounts in soy, corn, beef, turkey, and 
pork (16-18).  EPA and DHA, however, are found in large quantities in fish and 
are typically more abundant in the cell membranes of humans consuming a 
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“Mediterranean diet.” Regardless of diet, however, the ω-6 fatty acids compose 
the majority of fatty acids in human cell membranes.   
 Upon stimulation (such as insult or injury), AA, LA, EPA, and DHA are 
released from cell membranes via the activation of phospholipases, mainly 
cytosolic phospholipase A2 (cPLA2).  Once released from the phospholipid 
bilayer, AA, LA, EPA, and DHA can be metabolized by three main enzymatic 
pathways: the cyclooxygenase pathway (COX-1 and COX-2), the lipoxygenase 
pathway (5-LOX, 12-LOX, and 15-LOX), and the cytochrome p450 pathway 
(CYP) (fig. 1.1).   
 
B. Cyclooxygenases (COX-1 and COX-2) 
 The cyclooxygenase (COX) enzymes [also called prostaglandin 
endoperoxide H synthases (PGHS)] are responsible for the production of 
prostaglandins (PG) and thromboxanes (TX) (19, 20) (fig. 1.2).  There are two 
isoforms of COX, COX-1 and COX-2 (PGHS-1 and PGHS-2, respectively) (20).  
These isoforms both catalyze the same two reactions: the cyclooxygenation (bis-
oxygenation) of AA into prostaglandin G2 (PGG2) via addition of two molecules of 
O2 and the subsequent peroxidation of PGG2 to prostaglandin endoperoxide H2 
(PGH2) via reduction of two electrons (20).  The cyclooxygenase reaction takes 
place in a hydrophobic channel in the enzyme’s core while the peroxidase 
reaction takes place at a heme-containing active site at the protein’s surface (20).   
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Fig. 1.1. The Major Metabolic Pathways of Eicosanoid Generation (21). 
Arachidonic acid (AA) (as well as LA, EPA, and DHA) can be metabolized by the 
cyclooxygenase (COX) pathways to generate prostaglandins (PG) and 
thromboxanes (TX), the lipoxygenase (LOX) pathways to generate leukotrienes 
(LT) and hydroxyeicosatetraenoic acids (HETE), or the cytochrome P450 (CYP) 
pathway to generate the epoxyeicosatrienoic acids (EET). (Adapted from 
Panigrahy, D. Cancer Metastasis Rev. 2010) (21). 
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Fig. 1.2. Cyclooxygenase enzymes metabolize arachidonic acid into 
prostaglandins and thromboxanes (22).  Cyclooxygenase coordinates the 
conversion of AA into PGG2 and PGH2, which is further metabolized via specific 
synthases into prostaglandins and thromboxanes.  The function of these 
molecules depends on the tissue localization and expression of cognate 
receptors. [Adapted from Fries, S. Hematology Am Soc Hematol Educ Program. 
2005 (22)]. 
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 Despite the fact that the function of COX-1 and COX-2 is enzymatically 
identical, the two enzymes are differentially regulated both spatially and 
temporally.  While COX-1 localizes to the nuclear envelope, COX-2 is found in 
the smooth endoplasmic reticulum (23, 24).  Furthermore, while the expression of 
COX-1 is constitutive in most tissues, COX-2 is typically stimulation-dependent 
(25-28).  Thus, early prostaglandin synthesis is typically derived from COX-1 
(29). 
 
C. Lipoxygenases (5-LOX and 12/15-LOX) 
 The lipoxygenases are responsible for the production of leukotrienes (LT), 
hydroxyeicosatetraenoic acids (HETE), and for precursors of the lipoxins (LX), 
resolvins (Rv), and protectins (PD) (fig. 1.3).  There are numerous forms of 
lipoxygenase, including 5-LOX, 12-LOX, and 15-LOX, the numerical value 
referring to the carbon atom of arachidonic acid which bears the hydroperoxy 
group upon oxygenation (30).  In human cells, 12- and 15-LOX are separate 
enzymes; however, the homolog to these enzymes in murine cells is one 
enzyme, 12/15-LOX.  12- and 15-LOX are cytosolic (31, 32) while 5-LOX is found 
in both the nucleus and cytoplasm (33) and while 12/15-LOX is expressed in 
many immune and non-immune cells (34), 5-LOX expression is mostly confined 
to cells of myeloid lineage (14, 35). 
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Fig. 1.3. Lipoxygenase enzymes metabolize AA into leukotrienes (36).  5-
lipoxygenase oxygenates AA into 5-HPETE, which is further converted into LTA4.  
LTA4 can be converted into a variety of LTs, including LTB4, LTC4, LTD4, and 
LTE4.  [Figure adapted from Steinhilber, D. Front Pharmacol. 2010. (36)].  
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 In contrast to COX-2, 5-LOX activity does not require upregulation.  
Rather, 5-LOX activity requires the translocation of 5-LOX to the nuclear 
membrane and its association with five-lipoxygenase activating protein (FLAP).  
This process is stimulated by intracellular Ca2+ flux and activation of cPLA2 (33). 
Upon activation, 5-LOX oxygenates AA into 5-hydroperoxy-6,8,11,14-
eicosatetraenoic acid (5-HPETE) which is further converted into leukotriene A4 
(LTA4) via the elimination of the hydroxyl moiety from the hydroperoxy group 
(37).  LTA4 can be further converted by LTA4 hydrolase (LTA4H) into leukotriene 
B4 (LTB4) (38-40).  Alternatively, a glutathione transferase (LTC4 synthase) can 
convert LTA4 into LTC4 (41).  Further removal of a glutamic acid moiety via the 
action of a γ-glutamyl transpeptidase will yield LTD4 (42), which can be 
converted to LTE4 by the removal of glycine via a dipeptidase reaction (43).  
Collectively, LTC4, LTD4, and LTE4 are referred to as the cysteinyl leukotrienes 
(cysLT). 
 Many metabolites require the cooperation of multiple LOX enzymes for 
their production.  The production of lipoxins (e.g.: LXA4), for example, requires 
both the 12/15-LOX and 5-LOX pathways and can occur via two mechanisms: 1) 
A 5-LOX-expressing myeloid cell can produce LTA4 which is metabolized into 
LXA4 by a 12/15-LOX-expressing cell (e.g.: platelet) (44) or 2) a 12/15-LOX 
expressing cell can produce 15-HETE which is metabolized into LXA4 by 5-LOX 
(45).  These processes, wherein once cell produces a substrate that is 
metabolized by another cell, are examples of transcellular biosynthesis. 
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III. EICOSANOIDS IN INFLAMMATION 
 Eicosanoids are known to play an important role in the regulation of 
homeostatic mechanisms in the gut (46), the kidney (47), the vasculature (48), 
and the cardiovascular and reproductive systems (49-51).  Eicosanoids are also 
important mediators of both the innate and adaptive immune systems.   
 
A. Cyclooxygenase (COX) and inflammation 
 Historically, the COX-1 isoform of COX has been associated with 
homeostatic regulation while the COX-2 isoform has been associated with 
inflammation.  This is mostly due to the fact that COX-1 is constituitively 
expressed in most tissues (25, 28) while COX-2 expression, for the most part, is 
inducible (stimulation-dependent) (26, 27).  Evidence that COX-2 is upregulated 
on immune cells during inflammation has further supported this view (25, 52, 53).  
However, studies identifying COX-2 as important for the homeostatic regulation 
of the gut, brain, kidney, heart, and female reproductive system have somewhat 
challenged the categorization of COX-2 as “the inflammatory COX” (28, 54-56).  
Furthermore, data showing that COX-2-specific drugs (COXIBs) do not reduce 
the production of prostaglandins (PG) involved in inflammatory processes to the 
extent of dual COX-1/COX-2 inhibition [non-steroidal anti-inflammatory drugs 
(NSAIDs)] suggests that there exists at least a small role for COX-1 in the 
production of immune-modulating PGs (57-59). 
 The major PGs involved in inflammation are PGD2 and PGE2 and the net 
function of COX-2 expression is somewhat dependent on a balance of the 
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production of these two metabolites.  During an inflammatory response (e.g.: 
carrageenan-induced pleurisy), there are typically two peaks of COX-2 
expression (fig. 1.4) (60). The first peak, which occurs ~2 hours post-
carrageenan injection, is correlated with the onset of inflammation, the influx of 
polymorphonuclear leukocytes (PMNs) and PGE2 production.  The second peak, 
which occurs between 24 and 48 hours, correlates with the resolution of 
inflammation, mononuclear cell influx, and PGD2 production (60).  COX-2 
expression during the second peak is also much higher.  Thus, COX-2 functions 
as an immuno-regulatory enzyme in that it is involved in both the induction and 
resolution of inflammation. 
 PGD2 is typically classified as an anti-inflammatory eicosanoid, although it 
has also been implicated to be pro-inflammatory in models of asthma and 
hypersensitivity.  It has been shown that PGD2 decreases dendritic cell (DC) 
migration to the draining lymph nodes (dLN), which diminishes T-cell responses 
and promotes a worse outcome for viral infections (61).  This has proved to be a 
hazardous side effect of naturally increased PGD2 production in the elderly, as it 
leads to decreased ability to combat infection.  However, PGD2 also induces 
memory CD4+ T-lymphocyte trafficking during inflammation and exacerbates 
bronchial asthma by promoting vasodilation and increasing vascular permeability 
(62, 63).   
 Two major receptors for PGD2 exist: 1) chemoattractant receptor 
homologous molecules expressed on Th2 cells (CRTH2); and 2) D prostanoid  
 
13 
 
 
 
 
 
Fig. 1.4. COX-2 has a bimodal expression pattern during an inflammatory 
response (13).  In a model of carrageenan-induced pleurisy, it was 
demonstrated that COX-2 expression occurs in two peaks.  The first peak 
correlates with onset of inflammation, polymorphonuclear leukocyte infiltration, 
and PGE2 production, while the second peak correlates with the resolution of 
inflammation, mononuclear cell influx, and PGD2 production (60). [Adapted from 
Gilroy, D. & Colville-Nash, P.R. J Mol Med. 2000 (13)]. 
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receptor (DP).  In a model of contact hypersensitivity (CHS) in mice, stimulation 
of the CRTH2 receptor promoted a hypersensitivity reaction while stimulation of 
the DP receptor had inhibitory effects on CHS (64).  Thus, it appears that the 
contrasting pro- and anti-inflammatory functions of PGD2 may be receptor-
mediated, making the function of PGD2 temporally- and tissue-regulated 
depending on which tissue expresses which receptor and when.   
 15d-PGJ2 is the dehydration product of PGD2 and is classified as an anti-
inflammatory mediator because it binds to the nuclear peroxisome proliferator-
activated receptor gamma (PPARγ).  This results in the inhibition of NF-κB 
activation and a subsequent decrease in the production of NF-κB-regulated pro-
inflammatory metabolites (cytokines, chemokines, and eicosanoids) (65-68).  The 
majority of studies examining 15d-PGJ2 as a ligand of PPARγ, however, have 
been investigated in vitro.  Thus, its role as a natural, endogenous ligand of 
PPARγ and potent anti-inflammatory molecule in vivo remains inconclusive. 
 The function of PGE2, like PGD2, is context dependent and appears to be 
reliant on 1) the quantity of PGE2 produced (concentration) and 2) receptor 
expression (temporal- and tissue-dependent).  Large concentrations (in the high 
nanomolar to micromolar range) of PGE2 are immunosuppressive.  This has 
been demonstrated in cancer and tumor models, as tumor cells overexpress 
COX-2 and produce large quantities of PGE2 (69).   
 PGE2 exhibits a wide range of immunosuppressive effects, including the 
suppression of natural killer (NK) cell cytotoxicity (70); the induction of FOXP3 in 
T-cells and stimulation of IL-10 production by dendritic cells (DCs), which 
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promotes T-regulatory (T-reg) cell development and expansion (71); the inhibition 
of granulocyte function (granule release and phagocytosis) (72); and the 
inhibition of phagocytosis and killing by alveolar macrophages (73).  The ability of 
PGE2 to suppress NK cell, DC, granulocyte, and macrophage function as well as 
promote a T-regulatory phenotype, inhibit apoptosis (74), and promote tumor cell 
proliferation (69), make it a powerful player in the tumor microenvironment.  
COX-2 overexpression and PGE2 production are so commonly correlated with a 
poor prognosis in cancer diagnoses that many studies suggest that COX-2 
should be a prognostic marker for cancers such as melanoma (75).  On a more 
positive note, however, studies using NSAIDs and COXIBs are proving to be 
successful preventatives for various forms of cancer (76-81).  One study reported 
that regular use of aspirin was able to decrease the long-term risk of several 
types of cancer as well as decrease the risk for metastasis (76). 
 Outside of the tumor microenvironment, however, PGE2 can also function 
as an immunosuppressor indirectly.  For example, PGE2 is believed to mediate 
the “switch” from the production of 5-LOX to 15-LOX enzymes in human 
peripheral blood neutrophils (82).  This switch is required for the subsequent 
production of the pro-resolution molecule, lipoxin A4 (LXA4).  In a model of murine 
collagen-induced arthritis (CIA), COX-2 inhibition resulted in defective resolution 
of arthritis.  Treatment with PGE2 restored resolution due to its stimulation of the 
production of LXA4 (83).   
 PGE2 is also important for the suppression of inflammation in response to 
infection of the gastro-intestinal (GI) tract (84).  In the case of GI infection, 
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commensal bacteria stimulate the production of PGE2 by inflammatory 
macrophages, which inhibits neutrophil activation.  In the absence of 
inflammatory macrophages or when PGE2 is inhibited, GI infection results in 
severe neutrophil-mediated pathology.  Thus, commensal bacteria limit 
inflammation resulting from infection via stimulation of PGE2 production by 
inflammatory macrophages (84). 
 PGE2 is also renowned for the role it plays as an immuno-activator.  It is 
able to promote the influx of neutrophils and macrophages via stimulation of the 
production of the chemokines CXCL1 and MCP-1, respectively (85, 86).  It is also 
able to stimulate the influx and degranulation of mast cells (87-89).  Furthermore, 
it promotes a skewing of CD4+ T-helper (Th) cell differentiation toward that of 
Th2 and Th17 responses.  It does this by inhibiting the production of Th1-
promoting IFNγ, but not Th2-promoting IL-4 or IL-5 (89, 90).  It also inhibits the 
production of IL-12 by DCs while promoting the production of IL-23, leading to 
the production of IL-17-producing Th17 cells, which are instigators of arthritis, 
multiple sclerosis, Crohn’s disease, and irritable bowel syndrome (91). 
 In terms of inflammatory diseases such as arthritis, PGE2 is believed to be 
pro-inflammatory.  Deletion of microsomal PGE synthase (mPGES), which 
catalyzes the conversion of PGH2 to PGE2, results in attenuated arthritis in the 
CIA model (92).  The contribution of PGE2 to arthritic inflammation in this model 
is due to defective development of a humoral immune response and skewing of 
the IL-23/IL-17 axis (92, 93).  PGE2 also contributes to atherosclerotic 
inflammation via stimulation of arterial thrombosis (94) and experimental Crohn’s 
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disease via skewing of the T-helper cell compartment toward a Th17 phenotype 
(95).   
 The vast array of functions that PGE2 exhibits is due to the fact that it is 
able to signal through four separate receptors: E prostanoid receptor 1 (EP1), 
EP2, EP3, and EP4.  Furthermore, EP3 has three isoforms (96).  Regulation of 
these receptors is often tissue-, time-, and stimulation-dependent throughout the 
body, making the effects of PGE2 extremely circumstantial and highly regulated. 
 
B. Lipoxygenase (LOX) and inflammation 
 The function of lipoxygenase products is much less ambiguous than the 
function of prostaglandins.  For the most part, leukotrienes such as LTB4 and 
LTC4 are pro-inflammatory, while lipoxins, resolvins, and protectins are anti-
inflammatory. 
 LTB4 exerts many actions on innate immune cells.  Perhaps most 
noteworthy is the requirement for LTB4 for phagocytosis and for the enhanced 
expression of the myeloid differentiation primary response 88 (MyD88) protein, 
both of which serve primary functions in the innate immune response.   
 Cyclic adenosine monophosphate (cAMP) is a second messenger with a 
wide range of functions, including the inhibition of phagocytosis.  Although the 
exact mechanism by which cAMP regulates phagocytosis is unknown, it is 
suggested that it mediates F-actin polymerization (97-99).  LTB4 signaling 
through its receptor BLT-1 leads to a decrease in cAMP and enhances 
phagocytosis of pathogenic and non-pathogenic particles (e.g.: Klebsiella 
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pneumoniae, Streptococcus pneumoniae, immunoglobulin-coated sheep red 
blood cells) (100-102).  LTB4 and PGE2 have contrasting roles in the regulation of 
phagocytosis.  PGE2 signals through its EP2 receptor to stimulate an increase in 
cAMP, which inhibits phagocytosis (73, 103).  LTD4 is also able to augment 
phagocytosis, however, it does this in a cAMP-independent fashion (104). 
 LTB4 also functions to enhance the expression of MyD88, an adapter 
molecule that is required for the signaling pathway downstream of all toll-like 
receptors (TLR) except TLR3 (105).  LTB4 signaling through BLT-1 inhibits 
suppressor of cytokine signaling 1 (SOCS1).  SOCS1 suppresses MyD88 protein 
expression, thus inhibition of SOCS1 by LTB4 enhances MyD88 expression.  
This results in enhanced downstream signaling via NF-κB (105).  LTB4 is also a 
potent neutrophil chemoattractant and mediates the migration of gamma delta T-
cells in response to diverse stimuli (106, 107). 
 Due to its enhancement of immune cells functions, LTB4 is an important 
component of the innate immune response.  Several studies have reported that 
in its absence [or in the absence of its cognate receptor(s)], immune function is 
reduced and the ability to clear infection is dampened.  For example, 5-LOX 
knockout (5-LOX-/-) mice have increased mortality resulting from infection with 
Klebsiella pneumoniae due to reduced alveolar macrophage phagocytic and 
bactericidal abilities (108). 
 However, due to the potency of LTB4 as an immunoactivator, it also has a 
well-recognized role in pathogenic inflammation.  It is responsible for the 
inflammation that develops in the K/BxN serum transfer model of rheumatoid 
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arthritis by mediating the recruitment of neutrophils, enhancing the invasive 
behavior of fibroblast-like synoviocytes (FLS), and promoting pannus tissue 
formation and joint erosion (106, 109, 110).  Furthermore, the cysteinyl 
leukotrienes are highly involved in the pathogenic mechanisms involved in 
asthma (111, 112). 
 Although LTB4 functions, for the most part, as an immunoactivator, it also 
plays a protective role in the gastric mucosa.  LTB4 has two receptors; BLT-1, 
which mediates its effects on neutrophil recruitment and phagocytosis; and BLT-
2, about which less is known.  The stimulation of LTB4 through BLT-2 on colon 
cryptic cells protects against dextran sodium sulfate (DSS)-induced colitis.  It is 
believed that LTB4/BLT-2 exerts this effect by enhancing colon epithelial cell 
barrier function (113). 
 5-LOX is also important for the production of the anti-inflammatory/pro-
resolving metabolites lipoxins (LX), resolvins (Rv), and protectins (PD).  Although 
the substrate for LX production is AA, the substrate for Rv and PD is EPA and/or 
DHA.  Lipoxin A4 (LXA4) has a wide range of anti-inflammatory functions.  It 
inhibits vascular endothelial growth factor (VEGF)-stimulation of VEGF receptor 
phosphorylation, which results in decreased phosphorylation of phospholipase 
Cγ, extracellular signal regulated kinase (ERK) 1 and 2, and protein kinase B 
(Akt), which results in the inhibition of pro-inflammatory cytokines such as IL-6, 
TNFα, IFNγ, IL-8, and ICAM and the enhancement of the anti-inflammatory 
cytokine IL-10 (114).  Lipoxin A4 and protectin D1 (PD1) are both independently 
able to dampen airway inflammation and hyper-responsiveness associated with 
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asthma (115, 116) and EPA-derived resolvin E1 (RvE1) dampens LTB4/BLT-1 
signals on leukocytes and inhibits the recruitment of PMN (117).   
 
IV. LYME ARTHRITIS AS A MODEL OF INFLAMMATION 
 The Centers for Disease Control and Prevention (CDC) classifies arthritis 
as a class of diseases and conditions that affects the joints and connective tissue 
(rheumatic disease) with over 100 types, the most common of which is 
osteoarthritis (118).  Arthritis is characterized by pain, aching, stiffness, and 
swelling of the joints and is the most common cause of disability in the United 
States.  According to a 2013 CDC report, approximately 50 million (1 in 5) US 
adults have doctor-diagnosed arthritis and this number is expected to jump to 67 
million by 2030 (118). 
 The most commonly used animal models of arthritis are chronic or 
autoimmune in nature, such as collagen-induced arthritis, collagen antibody-
induced arthritis, and K/BxN serum transfer arthritis.  These models are 
beneficial for the study of mechanisms involved in the development and peak of 
arthritis, but leave a very important gap in the knowledge about a typical arthritic 
response: how does arthritic inflammation resolve under normal circumstances?  
These models are dependent on the development of autoantibodies and 
autoimmunity.   In experimental models, the resolution of these arthritides 
coincides with the degradation of these autoantibodies [e.g.: anti-glucose-6-
phosphate (GPI) autoantibodies transferred into recipient mice in the K/BxN 
serum transfer model].  However, the relevance of an immune response to 
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autoantibodies is not all encompassing for the study of rheumatic disease.  For 
example, it is hypothesized that inflammation that develops during rheumatoid 
arthritis is instigated by autoantibodies to “rheumatoid factor (RF).”  However, RF 
is only about 70% specific to rheumatoid arthritis and a number of other 
autoantibodies have failed to be diagnostic as well (119).  Furthermore, it is 
difficult to translate results from animal models in which arthritis is instigated by a 
specific origin to human rheumatic disease in which the causes are often 
multifaceted and unidentified. 
 The fact that the cause is unknown in most cases of arthritis has made 
developing successful therapeutics and treatments quite difficult.  With the 
discovery of novel anti-inflammatory/pro-resolving molecules (LX, Rv, and PD) 
has come an ideological shift in the study of arthritis.  Whereas, in the past, 
research focused on identifying key pro-inflammatory molecules that aided in the 
development of arthritis (e.g.: TNFα, IL-6, PGE2, LTB4), it is now recognized that 
strategically targeting molecules that aid in promoting the resolution of arthritis 
could be beneficial.  This ideological shift, however, has led to the necessity of 
models that allow the study of all phases of an inflammatory response: the 
development, the peak, and the resolution. 
 Lyme disease is the most common vector-borne disease in the United 
States and Europe (120, 121).  Dr. Alan Steere and colleagues first described the 
disease in 1977 in an effort to identify the cause of an outbreak of juvenile 
rheumatic disease in Lyme, Connecticut (122).  A spirochete isolated specifically 
from Ixodes ticks was identified as the causative agent by Dr. Willy Burgdorfer in 
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1982 and was so-named Borrelia burgdorferi (Bb) (123).  Human Lyme disease 
results from the bite of an infected Ixodes scapularis tick.  Early manifestations of 
disease include mild flu-like symptoms and may include a diagnostic bulls-eye 
shaped rash.  At this stage, disease is treatable with antibiotics such as 
Doxycycline.  However, if allowed to progress, Lyme disease can manifest in a 
severe polyarthritis localizing to the large joints and severe carditis (121, 124). 
 After years of effort trying to develop a laboratory animal model for Lyme 
disease, a murine model was established by Dr. Steven Barthold and his 
colleagues at Yale University (125).  The mouse model of Lyme arthritis mimics 
the human disease very well in that inoculation of mice with Bb results in joint 
and cardiac inflammation (126).  Furthermore, human disease symptoms often 
appear cyclic in that they are remitting and recurring, a disease phenotype that is 
also present in the mouse model (127).   In this mouse model, it is suggested 
that this phenomenon could either be due to neutralized Bb regaining 
pathogenicity or spirochetal antigen deposits persisting near cartilage (128, 129). 
 The exact mechanisms that mediate the development of Lyme arthritis 
and carditis remain elusive.  However, it was identified early on that a genetic 
component was involved in the regulation of experimental Lyme disease 
development.  In response to infection with Bb, C3H/He, SWR, and CB.17 
(SCID) mice develop severe arthritis while C57BL/6, BALB/c, and SJL mice 
appear resistant to disease (130, 131).  Similarly, C3H/He, but not C57BL/6, 
mice are susceptible to carditis (126).  Notably, Bb can be detected in the hearts 
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and joints of all strains, indicating that the difference between the strains is in 
their genetic susceptibility to disease, not infection. 
 Production of the chemokine KC signaling through the CXCR2 receptor 
and subsequent recruitment of neutrophils is required for the development of 
Lyme arthritis (132-134) and neutrophils are the predominant infiltrating cell 
during the peak of arthritic disease (125) while macrophages predominate during 
Lyme carditis (135).  Bb-specific antibodies are thought to mediate the clearance 
and eventual resolution of Lyme arthritis as SCID mice develop chronic 
inflammation and the passage of immune serum from infected mice results in the 
resolution of arthritic inflammation in recipient mice (136, 137).  The development 
of anti-Bb antibodies is T-cell-independent, as resolution is independent of MHC 
II, CD4+ T-cells, and CD40 ligand (138, 139). 
 Not only does murine Lyme arthritis offer an excellent model for a relevant 
human disease, but it also serves as a beneficial model of arthritis in which the 
induction, peak, and resolution of the inflammatory response are evident.  The 
transient nature of this model and the fact that it does not rely on a specific 
autoimmune compartment make it an excellent tool for the study of arthritis.   
 
V. EICOSANOIDS IN LYME ARTHRITIS 
 As eicosanoids comprise a major component of the innate immune 
response, it may be expected that they are heavily involved in the processes 
involved in Lyme arthritis, and this is indeed the case.  COX-2 is upregulated in 
the joints of mice infected with Bb and treatment of mice with the COX-2 specific 
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inhibitor 3-(3,4 difluorphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(5H)-furanone (MF 
Tricyclic) results in lessened arthritis severity (140).  However, while mice 
deficient in the enzyme COX-2 (COX-2-/-) have slightly attenuated arthritis 
severity, this inhibition results in a chronic arthritis, suggesting that COX-2 
metabolites play a role in the resolution of Lyme arthritis (141).  5-LOX-/- mice 
exhibited a similar chronic phenotype (142), perhaps due to defective LXA4 
production, which requires this pathway.   
 C57BL/6 mice deficient in COX-1 have no discernible defect in the 
development or resolution of arthritis, but are defective in their ability to form 
germinal centers and produce IL-6 and IL-17.  These defects correlated with a 
defect in antibody class switching and reduced Bb-specific immunoglobulin G 
(IgG) production.  Furthermore, sera from these mice had reduced bactericidal 
activity (143).   
 Lipidomic analysis of eicosanoids produced throughout the course of 
Lyme arthritis reveals that pro-inflammatory prostaglandins and leukotrienes are 
produced early during disease, while the peak of pro-resolving molecule (e.g.: 
15d-PGJ2 and PD1) production correlates with the peak of inflammation, likely 
promoting the process of resolution (144).  Lipidomic analysis of COX-2-/- mice 
suggests that deletion of this enzyme also affects the lipoxygenase pathway, as 
COX-2-/- mice have reduced production of numerous LOX metabolites (144).  
This may suggest that the chronic arthritis that arises in COX-2-/- mice may be 
due to defective LOX signaling and thus defective production of the pro-resolving 
metabolites produced via this pathway.  While this information confirms a role for 
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eicosanoid enzymatic pathways in the regulation of Lyme arthritis, the elucidation 
of the individual eicosanoids important for these processes remains to be 
completed. 
 Inflammation is a vital process required for the protection of tissues from 
insult or injury.  The resolution of inflammation, however, is an important 
component of the inflammatory response.  Inflammatory responses that are 
defective in the process of resolution become pathogenic (chronic inflammatory 
disease).  With a defined induction, peak, and resolution phase of inflammation, 
Lyme arthritis is an excellent tool for the study of inflammation.  Eicosanoids are 
small, potent lipids that play a large role in the modulation of both the innate and 
adaptive immune compartments and are major regulators of inflammatory Lyme 
arthritis.  Using murine Lyme arthritis as a model for the elucidation of 
mechanisms by which eicosanoids regulate inflammation and immunity will 
provide valuable insights into key pathways that may play a role in the 
development of chronic inflammation.  A more thorough understanding of these 
pathways will aid in the identification of potential therapeutic targets for the 
treatment of chronic inflammatory diseases such as severe arthritis. 
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CHAPTER TWO 
METHODS & MATERIALS 
 
I.  ANIMALS 
A. Control Mice 
 C3H/HeJ mice were obtained from The Jackson Laboratories (Bar Harbor, 
ME). 
      
B. KC-/- Mice 
 C3H KC-/- mice were generated by Charles R. Brown using speed 
congenics.  B6/129 KC heterozygote males (a generous gift from Sergio Lira, 
Mount Sinai School of Medicine) were backcrossed onto the C3H background for 
5 generations.  C3H KC heterozygote males and females were then crossed to 
create C3H KC-/- mice.   
 
C. KRN, NOD, and K/BxN Mice 
 KRN mice were a kind gift from Diane Mathis at Harvard Medical School.  
NOD mice were obtained from The Jackson Laboratories.  KRN males were bred 
to NOD females in order to generate K/BxN pups.  Pups were monitored for the 
development of arthritis.  Retro-orbital eye bleeds were performed on pups that 
developed arthritis.  Eye bleeds were performed once a week for five weeks on 
alternating eyes.  Mice were sacrificed on the 5th week via cardiac puncture.  
Serum was collected and stored at -20°C for future use. 
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D. COX-2-/- Mice 
 COX-2-/- mice were purchased from The Jackson Laboratories (B6; 129S-
Ptgs2tm1Jed/J).  Mice were backcrossed for ten generations onto the C3H/HeJ 
background. 
 
D. Housing and Experimental Conditions 
 Mice were housed in a specific pathogen-free, environmentally stable (12 
hour dark/light cycle, 23°C, 40-50% relative humidity) facility.  Unless otherwise 
mentioned, mice were fed commercial rodent diet (Purina Mills) & given water ad 
libitum.  Mice were allowed 5 day acclimation periods prior to use in experiments.  
Experimental mice were age and sex matched if possible.  All studies were 
conducted in accordance with the Animal Care and Use Committee of the 
University of Missouri. 
 
II.  EXPERIMENTAL DIETS 
A. Fish Oil Diets  
 Fish oil and control diets were constructed by Kevin L. Fritsche (University 
of Missouri-Columbia) (145).  Experimental diets were based on the AIN-93G 
rodent diet (146, 147) and were constructed so that the nutrient-to-energy ratio 
was not altered compared to normal rodent diet when modified to contain 18% 
fat.  The “control” diet was supplemented with soy oil (SO) and the “experimental” 
diet was supplemented with a mixture of Menhaden fish oil (FO) and SO in a 4:1 
ratio.  SO was added to the FO diet in order to ensure that essential fatty acid 
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requirements were met.  Both diets were identical except major dietary fat 
sources and contained 375-g/kg corn starch, 230-g/kg casein, 110-g/kg sucrose, 
57-g/kg α-cellulose, 40.2-g/kg AIN-93G mineral mix, 11.5-g/kg AIN-93G vitamin 
mix, 3.4-g/kg L-cysteine, 2.9-g/kg choline bitartrate, and 180-g/kg dietary fat 
sources.  Dietary fats included in the chows were as follows (expressed as 
percent of total fatty acids in either the SO or FO diet, respectively): 0.2 or 4.5% 
myristic acid (14:0); 10.9 or 17.6% palmitic acid (16:0), 5.0 or 3.5% stearic acid 
(18:0); 23.8 or 16.8% oleic acid (18:1), 52.8 or 12.7% linoleic acid [18:2(n-6)]; 
and 6.4 or 1.6% α-linolenic acid [18:3(n-3)].  The FO diet also included 15.9% 
eicosapentaenoic acid (EPA) [20:5(n-3)]; 2.9% docosapentaenoic acid [22:5(n-
3)]; 12.0% docosahexaenoic acid (DHA) [22:6(n-3)]; 7.1% palmitoleic acid 
[16:1(n-7)]; 1.6% cis-vaccenic acid [18:19n-7)]; 2.7% stearidonic acid [18:4(n-3)]; 
and 1.0% eicosatetraenoic acid [20:4(n-3)].  Fat sources included 0.02% wt/wt 
tertiary butylhydroquinone in order to prevent auto-oxidation.  Mice were fed 
experimental diets for two weeks prior to infection with Bb.   
 
B. Celecoxib Diets 
 Celecoxib, a selective COX-2 inhibitor, was obtained from LKT 
Laboratories (St. Paul, MN) and incorporated into a normal rodent chow (Purina 
PicoLab 5053; Purina Mills, St. Louis, MO) at a dose of 1000 parts per million 
(ppm) by Research Diets (New Brunswick, NJ) (141, 148).  Control animals were 
fed normal rodent chow.  Mice were fed experimental diets for two weeks prior to 
infection with Bb. 
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III. FATTY ACID ANALYSIS 
 Serum and liver fatty acid extraction and analysis was performed by Dr. 
Kevin L. Fritsche (145, 149, 150).  Total cellular lipids were extracted from the 
serum and the liver (150) and resuspended in chloroform-methanol (2:1, v/v).   
The sample was applied to High Performance Thin-Layer Chromatography 
(HPTLC) Silica Gel 60 plates (Merck) and developed in hexane-diethyl ether-
acetic acid (85:15:12, v/v/v) for 30 minutes.  An air gun was used to remove 
solvent and then HPTLC plates were sprayed with 2’,7’-dichlorfluorescein 
(2.5mm/L methanol).  A UV lamp was used to visualize the phospholipid spot and 
scrape it into a 30-mL screw-capped tube with a Teflon-lined cap.  20-µg of 17:0 
fatty acid methyl esters (FAME) were added as an internal standard.  Trans-
methylation of fatty acids was achieved by the addition of 1.0-mL of 0.5 mol/L 
sodium hydroxide for ten minutes followed by 2-mL of chloroform for 10 minutes.  
FAME were extracted by adding 0.75-mL H2O.  Samples were filtered through 
sodium sulfate and analyzed by a Hewlett-Packard Model 5890 Gas 
Chromatograph equipped with a 30-m x 0.25-mm inner diameter-fused silica 
capillary column (Supelco) (149).  Comparing the relative retention times to that 
of commercial standards enabled identification of extracted FAME.  Data are 
expressed as moles per 100 moles of the total identified FAME (149). 
 
IV.  BACTERIA & INFECTIONS 
 A virulent, low-passage isolate of the N40 strain of Bb was used for in vivo 
infections and in vitro stimulations.  Aliquots of Bb N40 were stored at -80°C, 
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thawed in a 37°C water bath via swirling, and cultured in 7.5-mL Barbour-
Stoenner-Kelly II (BSK) media (151) containing 6% rabbit serum (Sigma-Aldrich) 
(cBSK).  Bb were allowed to grow to log-phase for 5 days at 32°C.  The Bb 
culture was diluted 1:100 in BSK for enumeration using a Petroff-Hausser 
counting chamber and dark-field microscopy.  For infection, Bb were diluted in 
BSK lacking rabbit serum to reach a concentration of 1 × 106/mL.  Both hind 
footpads of mice were inoculated with 50-µL of the culture, resulting in a final 
infectious dose of 1×105 Bb/mouse (or 5 × 104 per footpad).  For stimulation of in 
vitro cultured cells, Bb centrifuged at 10,000 × g for 3 minutes (152) and 
resuspended in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen). 
 
V.  ASSESSMENT OF JOINT SWELLING 
 Although some exceptions have been noted, ankle (tibiotarsal joint) 
swelling is typically a good indicator of the underlying immune response 
associated with Lyme arthritis (153).  Metric calipers were used to measure 
swelling through the craniocaudal portion of the ankle joint.  Ankle measurements 
were recorded on day 0 (prior to inoculation with Bb) and once or twice weekly 
thereafter.  Increases in ankle diameter were calculated by subtracting the day 0 
measurement from subsequent measurements. 
 Mice transferred K/BxN serum often developed joint swelling that was too 
severe to monitor via metric calipers.  Therefore, clinical scores were also used 
in order to assess gross arthritis severity.  Clinical scores were assigned as 
described by Monach, et al. (154) on a 0 – 3 scale.  A score of 0 indicated that 
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the joint was non-arthritic.  A score of 1 indicated either mild ankle/tendon sheath 
swelling or focal swelling of one or more digits.  A score of 2 indicated medium 
swelling of the joint. This score indicated that foot swelling was leading to the 
shape of the foot being altered.  Whereas in an un-swollen joint, the top of the 
foot (toes) is wider than the back of the foot (ankle), severe swelling would lead 
to the back of the foot being wider than the front of the foot.  A score of 3 
indicated maximum swelling, in which the entire foot was swollen. 
 
VI.  ASSESSMENT OF TISSUE PATHOLOGY & IMMUNOHISTOCHEMISTRY 
 Histological assessment of tissue inflammation was conducted by a board-
certified veterinary pathologist, Jennifer Hughes-Hanks.  Hearts (sagittally 
bisected through both ventricles and atria) and joints were fixed in 10% buffered 
zinc-formalin, mounted, and stained with hematoxylin and eosin (H&E).  Severity 
scores were on a 0 to 4 scale, with 0 representing no inflammation and 4 
representing severe inflammation (involving >50% of the sample).  Inflammation 
type scores, representing the ratio of neutrophils to macrophages, were on a 0 to 
4 scale and generated using the following criteria: 0 = few neutrophils or 
macrophages; 1= <5% neutrophils, >90% macrophages; 2= 5-25% neutrophils, 
>75% macrophages; 3= 25-50% neutrophils, 50-75% macrophages; 4= >50% 
neutrophils, <50% macrophages.  Inflammation type scores and the criteria used 
to generate them are based on data suggesting which cells mediate the different 
phases of Lyme carditis and arthritis (133, 135) and are valuable for the 
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histological assessment of the induction, peak, and resolution phases of an 
immune response. 
VII.  EXTRACTION OF DNA FROM TISSUES USING TRIZOL 
 Tissues including heart, ear, ankle (tibiotarsal joint), and knee were 
excised from mice and snap-frozen in liquid nitrogen.   In some instances, tissues 
were stored at -80°C until DNA extraction.  For DNA extraction, tissues were 
removed directly from liquid nitrogen into 2-mL screw-top microcentrifuge tubes 
(Sarsedt) containing approximately 500-µL Zirconia beads (Biospec Products) 
and 1-mL TRIzol (Invitrogen).  Samples were minced using sterile scissors and 
then placed in a Mini Bead Beater (Biospec Products) and homogenized for 2 
minutes, after which time they were allowed to cool to room temperature for 
approximately 5 minutes.  200-µL Chloroform was added to the samples, the 
samples were vortexed for 10 seconds, and then allowed to incubate at room 
temperature for 10 minutes.  Samples were then centrifuged at 12,000 × g for 30 
minutes at 4°C.  Supernatant was removed and 500-µL Back Extraction Buffer 
(4M guanidine thiocyanate, 50mM sodium citrate, q.s. to 100-mL with 1M Tris pH 
8.0) was added to the samples.  The samples were then vortexed, allowed to 
incubate at room temperature for 15 minutes, and then centrifuged at 12,000 × g 
for 15 minutes at 4°C.  Samples were collected from centrifuge and kept on ice.  
Supernatant was removed to a 1.5 mL microcentrifuge tube and 400-µL 
isopropanol was added.  Samples were vortexed, incubated at room temperature 
for 5 minutes, and then centrifuged at 12,000 × g for 5 minutes at 4°C.  
Supernatant was removed and the pellet was washed carefully with 500-µL 75% 
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ethanol.  Ethanol was removed from the tube and the DNA pellet was dried 
overnight in a biosafety cabinet.  DNA from the ears was dissolved in 100-µL 
double distilled water (ddH2O), while DNA from all other tissues was dissolved in 
200-µL double distilled water.  DNA was quantified using a NanoSpec and diluted 
to a 50 ng/mL for use in PCR (132). 
 
VIII.  QUANTIFICATION OF BORRELIA BURGDORFERI IN TISSUES 
 Enumeration of Bb in tissues was achieved using ABI Prism 7700 
Sequence Detection System (Applied Biosystems) for quantitative multiplex real-
time PCR.  Murine DNA was detected using primers and a probe for the single 
copy mouse gene, nidogen (nido) [Forward: 5’-CCAGCC ACA GAA TAC CAT 
CC-3’; Reverse: 5’-GGA CAT ACT CTG CTG CCA TC-3’ (155, 156); Internal 
oligonucleotide probe: 5’-VIC-AGC TCA GCC TGG CAG ACG CAA AGT-
TAMRA-3’ (132)].  Bb DNA was detected using primers and a probe for bacterial 
flagellin (flag) [Forward: 5’-TCT TTT CTC TGG TGA GGG AGC T-3’; Reverse: 
5’-TCC TTC CTG TTG AAC ACC CTC T-3’; Internal oligonucleotide probe: 5’-
FAM-AAA CTG C(TAMRA)TC AGG CTG CAC CGG TTC-3’] (157).  PCR 
reactions consisted of 10 µL ddH2O, 12.5-µL 2X TaqMan Universal PCR 
MasterMix (Applied Biosystems), 0.25-µL forward primer (150 nM final 
concentration), 0.25-µL reverse primer (150 nM final concentration), 0.25-µL 
probe (100 nM final concentration), and 1.0-µL DNA [which is estimated to 
contain 1000 copies of nido (155)] for a final reaction volume of 25-µL, in 
accordance with the manufacturer’s protocol.  The reaction proceeded at 50°C 
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for 2 minutes, 95°C for 10 minutes, and with 45 cycles of 95°C for 15 seconds 
and 60°C for 1 minute.  DNA isolated from a pure culture of Bb was used as a 
positive flag control, DNA isolated from uninfected murine tissue was used as a 
positive nido control, and a reaction containing no DNA was used as a negative 
control.  Bb DNA in each sample was quantified by comparing the ΔΔCT values 
obtained to a standard curve consisting of known numbers of Bb.  Normalization 
of mouse DNA in each sample was conducted similarly by comparing the ΔΔCT 
values obtained to a standard curve consisting of dilutions of murine DNA from 
the tissue in question (ear, ankle, knee, etc.) (132). Each sample was run in 
duplicate.  Copies of flag were normalized to copies of nido from in the same 
tube and results are expressed as copies of flag per 1000 copies of mouse nido. 
 
IX.  QUANTIFICATION OF TISSUE CYTOKINE & CHEMOKINE PRODUCTION  
 Tissues including heart, ankle (tibiotarsal), and knee were excised from 
mice and snap-frozen in liquid nitrogen as described (132).  In some instances, 
tissues were stored at -80°C until protein isolation occurred.  Tissues were 
removed from liquid nitrogen and wrapped in foil.  Foil-wrapped samples were 
then dipped in liquid nitrogen and smashed with a hammer.  Pulverized tissue 
was then transferred into 2-mL screw-top microcentrifuge tubes (Sarstedt) 
containing 1-mL Hank’s Buffered Saline Solution (HBSS) and Protease Inhibitor 
Cocktail (1:1000; company) (HBSS + PIC).  Samples were kept on ice at all 
times.  Samples were sonicated at 60% for 20 seconds and then centrifuged at 
8000 rpm for 10 minutes at 4°C.  Supernatant was removed from samples and 
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filtered using a 3-mL syringe attached to a 45-µm filter and collected into a fresh 
2-mL screw-top microcentrifuge tube.  Samples were q.s. to 1.5-mL with HBSS + 
PIC.  Tissue protein was quantified using Pierce bicinchoninic acid (BCA) Protein 
Assay Reagent (Thermo Scientific).  Tissue cytokines and chemokines were 
quantified via Enyzme Linked Immunosorbent Assay (ELISA).  KC, LIX, MIP-2, 
and TNF-α were detected using R & D DuoSet kits (R & D Systems) and IL-6 and 
IL-1β were detected using BD OptEIA kits (BD Biosciences).  Cytokine and 
chemokine quantities were normalized to total tissue protein and results are 
expressed as picograms cytokine or chemokine per milligram tissue protein. 
 
X.  EXTRACTION OF TISSUE EICOSANOIDS (144) 
 Ankle (tibiotarsal joint) tissue was excised from mice and snap-frozen in 
liquid nitrogen as described (144).  In some instances, tissues were stored at -
80°C until eicosanoid extraction occurred.  Tissue was removed from liquid 
nitrogen and wrapped in foil.  Foil-wrapped samples were dipped in liquid 
nitrogen and smashed with a hammer.  Smashed samples were again dipped in 
liquid nitrogen, and frozen tissue was transferred to a 16 × 100 mm glass test 
tube filled with 3-mL ice-cold 50% ethanol, 50-µL eicosanoid internal standard 
(supplied by the lab of Dr. Edward A. Dennis, University of California—San 
Diego), and 10-µL antioxidant cocktail (0.2 mg/mL butylated hydroxytoluene, 0.2 
mg/mL EDTA, 2 mg/mL triphenylphosphine, 2 mg/mL indomethacin in a solution 
of 2:1:1 methanol:ethanol:water) located on a tared scale in order to obtain tissue 
weight.  Test tube was capped and samples were kept on ice at all times.  
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Samples were vortexed, incubated at -20°C for 72 hours, and centrifuged at 3500 
rpm for 30 minutes.  Clear, ethanolic supernatant was removed to a 12 × 75 mm 
glass test tube and dried under nitrogen gas.  Dried samples were stored at -
20°C and shipped on dry ice to Darren S. Dumlao in Dr. Edward A Dennis’ lab at 
the University of California—San Diego for eicosanoid quantification.  
 
XI.  LC, MS, & EICOSANOID QUANTIFICATION 
 Lipidomic analyses were performed by Dr. Darren S. Dumlao in the lab of 
Dr. Edward A. Dennis at the University of California—San Diego (145) using a 
mass spectrometry (MS)-based approach (158).  Liquid chromatography (LC)-
grade solvents were from EMD Biosciences.  Strata-X Solid-phase Extraction 
Columns (Phemononex) were used to extract eicosanoids from dried samples 
into 1.0-mL methanol.  40-µL of the sample was separated by LC using a 
Synergy C18 Reverse-phase HPLC Column (Phemononex).  Eicosanoids were 
detected using a tandem quadrupole MS (ABI 4000 Q-TrapR, Analyst 1.5 
software, Applied Biosystems) via scheduled multiple reaction monitoring (MRM) 
in negative ion-mode (145).  Comparing the MRM signals and LC retention times 
to those of purified standards (Cayman Chemicals and Biomol) enabled 
identification of extracted eicosanoids.  Quantity of eicosanoid was standardized 
to total tissue weight and results are expressed as picograms eicosanoid per 
milligram tissue. 
 
 
37 
XII. TREATMENTS 
 15d-PGJ2, PGE2, and Butaprost were all purchased from Cayman 
Chemical (Ann Arbor, MI).  All treatments were made fresh prior to 
administration.  60-ng of 16d-PGJ2 in 100-µL PBS was delivered subcutaneously 
to mice on days 3 – 14 post-infection.  1.0-µg of PGE2 in 50-µL of PBS was 
delivered subcutaneously to mice daily throughout the course of a 35-day 
infection.  5-uM Butaprost in 100-µL PBS was delivered intraperitoneally on days 
5 – 7 and 12 – 15 post-infection.  PBS served as a vehicle control in all studies. 
 
XIII.  STATISTICAL ANALYSES 
Bacterial loads are expressed as individual data points with bars indicating 
median values.  Cytokine and chemokine data are expressed as means ± 
standard deviation.  Statistical significance of group means was analyzed using 
the Student’s t test (ELISA & EIA results) or the Mann-Whitney rank sum test 
(severity scores) with Prism 6 (GraphPad Software) (134, 145).  Significance 
levels were set at an α of 0.05.  Eicosanoid values in the lipidomic studies done 
in collaboration with D. Dumlao and E. Dennis were filtered using a Grubb’s test 
to remove outliers.  Values in these studies represent means ± standard error of 
the mean and significance was determined by 2-way ANOVA (P < 0.05).  
Significance for specific comparisons made in the collaborative studies was 
determined by ANOVA and the Dunnett’s post hoc test (metabolite changes over 
time on specific diet) or by Bonferroni’s post hoc multiple comparison test 
(metabolite changes between diets) (145). 
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CHAPTER THREE 
KC (CXCL1) MEDIATES THE DEVELOPMENT OF EXPERIMENTAL LYME 
DISEASE 
 
I. INTRODUCTION 
  The development of experimental Lyme disease is mediated by 
innate immunity (159, 160) suggesting that genetic factors determining 
susceptibility or resistance regulate this compartment.  In 2003, Brown, et al. 
surveyed the production of a panel of chemokines and cytokines in genetically 
susceptible (C3H/HeJ) and resistant (C57BL/6) mice and found that the 
chemokines KC (CXCL1) and monocyte chemoattractant protein-1 (MCP-1; 
CCL2) were upregulated in C3H/HeJ compared to C57BL/6 mice (132).  Infection 
of mice deficient in CCR2 (the receptor for CCL2) had no affect on disease 
severity in C3H/HeJ or C57BL/6 mice (132).  However, infection of C3H/HeJ 
mice deficient in CXCR2 (the receptor for KC) resulted in attenuated arthritis 
severity, while deficiency of CXCR2 on the C57BL/6 background had no effect on 
disease (132).  These data suggested that the ability of mice to develop disease 
in response to Bb infection was mediated by genetic factors regulating the 
production of CXCR2 ligands.  Signaling through CXCR2 mediates the 
recruitment of neutrophils and in its absence neutrophil extravasation into joint 
tissue was drastically reduced (132). This suggests that in susceptible mouse 
strains, the recruitment of neutrophils is required for disease. 
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 The results from Brown, et al. 2003 identified a role for CXCR2 in the 
recruitment of neutrophils and subsequent development of Lyme arthritis in 
response to infection with Bb.  Three ligands mediate their effects through 
CXCR2: KC (CXCL1); macrophage inflammatory protein 2 (MIP-2); and LIX 
(CXCL5). Although KC was expressed in higher quantities in susceptible mouse 
strains than resistant mouse strains, it was unclear whether this chemokine 
alone, signaling through CXCR2, mediated the development of arthritis.  
Furthermore, while the inhibition of neutrophil recruitment via deletion of CXCR2 
defined a role for this process in Lyme arthritis development, the effect of 
inhibiting neutrophil recruitment on Lyme carditis had not been determined. 
 The study described herein identified a critical role for the chemokine KC 
in the recruitment of neutrophils to sites of infection and subsequent development 
of Lyme arthritis and carditis. 
 
II. RESULTS 
A. KC mediates edema resulting from infection with Borrelia burgdorferi.   
 Neutrophil recruitment is known to be required for a variety of arthritis 
models, including CIA (161), CAIA (162), K/BxN (109, 163, 164), adjuvant-
induced arthritis (165), and streptococcal cell wall-induced arthritis (166).  
Neutrophils are also known to play a critical role in the development of human 
RA (167, 168).  Brown, et al. reported that absence of the potent chemokine 
receptor CXCR2 resulted in reduced neutrophil recruitment to the joint and 
attenuated Lyme arthritis (132).  As stated above, CXCR2 has three known 
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ligands: KC; MIP-2; and LIX.  KC was expressed in greater amounts in the joints 
of Lyme arthritis susceptible mice (C3H/HeJ) compared to Lyme arthritis resistant 
mice (C57BL/6) (132), hinting that the KC/CXCR2 axis mediates the 
development of Lyme arthritis. 
 To investigate the role of KC in Lyme arthritis, we infected wild type 
C3H/HeJ (WT) and C3H KC-/- mice with 5x104 of a virulent, low-passage isolate 
of Bb N40.  We used metric calipers to monitor ankle swelling, a typical symptom 
arising from infection with Bb, for 21 days. WT mice exhibited a typical course of 
disease, with progressive joint swelling following infection leading to a peak at 
around 17 days post-infection (fig. 3.1).  KC-/- mice, however, exhibited 
attenuated ankle swelling.  Ankle edema was significantly reduced at days 14 
and 17 post-infection compared to their WT counterparts.  This indicated that KC 
(most likely signaling through CXCR2) mediates ankle swelling associated with 
Lyme arthritis. 
B. KC mediates Lyme arthritis severity.   
 Although joint edema is typically indicative of the underlying inflammatory 
response associated with Lyme arthritis, some exceptions have been noted 
(153).  Therefore, to more thoroughly evaluate joint inflammation, we used H & E 
to stain joint sections taken on days 11 and 21 post-infection.  We assessed 
arthritis severity on a 0 – 4 scale, where 0 represented no inflammation and 4 
represented severe inflammation.  KC-/- mice exhibited significantly less arthritis 
severity on days 11 and 21 post-infection (fig. 3.2 A), indicating that KC 
mediates the severity of inflammation resulting from infection with Bb. 
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Fig. 3.1.  KC-/- mice have reduced joint edema in response to infection with 
Borrelia burgdorferi (134). WT and KC-/- mice were infected with 5×104 Bb via 
footpad inoculation.  Disease was allowed to progress for 21 days.  Throughout 
the course of infection, ankle swelling was monitored using metric calipers.  
Changes in ankle diameters were calculated by subtracting day 0 measurements 
from subsequent measurements.  Data are representative of four separate 
experiments, 8 mice per group.  Results are expressed as means ± SEM and * 
indicates a significant difference from control at the same time point (p < 0.04).
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Fig. 3.2.  KC-/- mice exhibit attenuated arthritis severity and altered joint cell 
infiltrate (134).  Joint sections from mice at days 11 and 21 post-infection were 
stained with H&E and arthritis severity (A) and type scores (B) were generated 
on a scale of 0 – 4.  Eight mice were in each group, data shown are means ± 
SEM, and * indicates a significant difference from WT at the same time point (p 
<0.05).  Assessment of histological sections and subsequent determination of 
arthritis severity scores and arthritis type scores was conducted by Jennifer 
Hughes-Hanks.
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 Based upon the type of cells that accumulated during joint inflammation, 
we were able to generate arthritis type scores.  These scores were based on the 
ratio of neutrophils to macrophages, as these are the two innate immune cells 
that predominate during Lyme arthritis (130).  Arthritis type scores are on a scale 
of 0 – 4, where 0 indicates few neutrophils or macrophages, 1 indicates a 
predominance of macrophages, and 4 indicates a predominance of neutrophils.  
It is believed that neutrophils mediate the early stages and development of 
arthritis and that macrophages predominate during the late stages and resolution 
of arthritis (130).  Therefore, a higher type score (more neutrophils) suggests 
acute inflammation, while a lower type score (more macrophages or fewer 
immune cells in general) suggests low levels of inflammation and resolution of 
disease.  KC-/- mice had significantly lower arthritis type scores, indicating that 
neutrophil infiltration was reduced in the joints of these mice (fig. 3.2 B).  This 
data suggested that KC mediated neutrophil infiltration into the joints during 
Lyme arthritis. 
 
C. Absence of KC leads to reduced neutrophil and macrophage joint 
infiltration.   
 To better assess the cell types present in the joints of WT and KC-/- during 
Lyme arthritis, we used immunohistochemical staining of joint sections to identify 
neutrophils and macrophages (RB6-8C5 and F4/80, respectively).  Significantly 
fewer RB6-8C5-labelled neutrophils were present in the joints of KC-/- mice 
compared to WT counterparts at day 21 post-infection (fig. 3.3) confirming the  
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Fig. 3.3.  KC-/- mice have significantly reduced neutrophil and macrophage 
infiltration into infected joint tissue (134).  Joint sections of WT and KC-/- mice 
were stained with the neutrophil marker RB6-8C5 (RB6) or the macrophage 
marker F4/80.  Representative sections from day 21 post-infection are displayed 
above.  Magnification X100.  Bar = 50µm.  Assessment of tissue pathology and 
joint cell infiltrate was conducted by Jennifer Hughes-Hanks. 
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requirement for KC for the recruitment of neutrophils to Bb-infected joints.  
Somewhat surprising was the finding that F4/80-labelled cells (presumably 
macrophages) were also greatly reduced in number in the joints of KC-/- mice 
(fig. 3.3).  This data suggests that KC is important for the recruitment of 
macrophages to the joint; however, whether this is a direct effect of KC or 
whether the defect in neutrophil recruitment in the absence of KC leads to a 
defect in subsequent production of macrophage chemotactic factors and thus 
macrophage recruitment is unknown. 
 
D. Absence of KC does not affect the ability of spirochetes to be cleared 
from joints of Bb-infected mice.   
 Neutrophils are known to play a large role in the clearance of Bb from 
tissues (169-171).  As neutrophils were drastically reduced in the joints of KC-/- 
mice, we hypothesized that the quantity of Bb in joint tissue would be increased.  
We used quantitative Real-Time PCR to detect copies of the Bb flagellin B (flab) 
gene in DNA from joint tissue at days 10, 21, and 35 post-infection and 
normalized them to 1,000 copies of the murine gene Nidogen (nido).  Although at 
days 10 and 35 post-infection the copies of Bb DNA in joints from KC-/- mice 
appeared to trend higher compared to Bb DNA in WT joints, these differences did 
not reach statistical significance (fig. 3.4 A).  As Bb tends to migrate to the ears 
of infected mice (125), we also assessed Bb numbers in ear tissue and found no 
difference between the numbers of Bb DNA in KC-/- tissue when compared to WT 
tissue (fig. 3.4 B).  This data implies that although KC-/- mice exhibited a defect in  
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Fig. 3.4.  KC-/- mice are able to clear Bb infection as well as WT mice (134).  
Joints and ears were removed from mice at days 10, 21, and 35 post-infection.  
Spirochete DNA was detected using quantitative Real Time PCR.  Copies of the 
Bb flagellin gene (FlaB) were normalized to 1000 copies of the mouse gene 
nidogen (Nido).  Data are representative of two separate experiments and bars 
indicate median values. 
Ankles Ears A B 
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the recruitment of both neutrophils and macrophages to infected joints, they were 
not impaired in their ability to clear infection. 
 
E. Joint cytokine and chemokine expression is unaffected by the absence 
of KC.   
 Besides contributing to the clearance of pathogens by phagocytosis, 
neutrophils also produce cytokines (109, 172-175), lipids (109, 176), and other 
immune factors that aid in the development of an immune response to infection 
(173, 177).  In an effort to assess whether the drastic reduction in neutrophils and 
macrophages in the joints of KC-/- mice had an effect on the cytokine milieu, we 
extracted protein from the joints of infected mice at days 11 and 21 post-infection 
and measured the expression of three classical cytokines: IL-6; TNF-α; and IL-
1β.  Despite the fact that KC-/- mice had far fewer neutrophils and macrophages 
in the joints at these time points, the expression of these cytokines was no 
different than in WT mice (fig. 3.5 A).  These results indicated that although KC 
deficiency affected the joint immune cell milieu, it did not affect the ability of these 
mice to produce relevant cytokines similar to WT levels.  These results also 
suggest that either other cells present in the joints during infection (fibroblasts, B-
cells, monocytes, non-F4/80-expressing macrophages, non-Gr-1-expressing 
polymorphonuclear cells (132), etc.) were producing the majority of these 
cytokines or that the limited number of neutrophils and macrophages present 
were able to produce quantities of these cytokines comparable to those  
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Fig. 3.5.  KC-/- mice are able to effectively produce cytokines and 
chemokines to WT levels (134).  On days 11 and 21 post-infection, joint tissue 
was removed and protein was extracted.  Levels of the cytokines IL-6, IL-1β, and 
TNF-α (A) and the chemokines KC, LIX, and MIP-2 (B) were quantified using 
ELISA.  No significant differences were noted between KC-/- mice and WT mice 
at any time point. 
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expressed in WT joints.  LIX and MIP-2 are two other chemokines that bind 
CXCR2 and aid in the recruitment of neutrophils and macrophages to sites of 
infection.  We were curious as to whether the expression of these two 
chemokines would be increased in order to compensate for the loss of KC 
signaling in the knockout mice. However, the expression of both LIX and MIP-2 
were no different in the joints of KC-/- mice when compared to their expression in 
the joints of WT mice (fig. 3.5 B). 
 Overall, these data suggest that, even with drastically reduced neutrophil 
and macrophage recruitment to sites of infection, mice were able to mount a 
successful immune response.  The fact that cytokine and chemokine expression 
was unchanged in the KC-/- mice may help to explain how these mice were able 
to clear infection despite the reduced numbers of macrophages and neutrophils 
in the joints.  
 
F. KC mediates Lyme carditis severity.   
 Besides arthritis, carditis is a significant sequelae that results from Bb 
infection in humans that is recapitulated by experimental murine Lyme borreliosis 
(126).  While the results from Brown, et al. and this study proved the KC/CXCR2 
axis mediated the development of Lyme arthritis, mechanisms that modulate the 
development of murine Lyme carditis have not yet been elucidated.  Therefore, 
we extracted and sagittally bisected the hearts of Bb-infected mice at days 11 
and 21 post-infection and assessed them histologically for carditis severity and 
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carditis type.  Carditis severity and type scores were assigned similarly to arthritis 
severity scores.   
 On day 11 post-infection, neither WT nor KC-/- had developed carditis, 
reflecting delayed dissemination of Bb to the heart (125, 178) (fig. 3.6 A).  
However, on day 21 post-infection, KC-/- mice had significantly reduced carditis 
severity (fig. 3.6 A) and type scores (fig. 3.6 B) compared to WT mice indicating 
that KC signaling plays a role in the development of murine Lyme carditis. 
 
G. Neutrophil and macrophage infiltration into heart tissue is altered in the 
absence of KC.   
 It is suggested that macrophages mediate the development and severity 
of Lyme carditis, as they are the dominant cell type present in cardiac lesions 
(126, 135, 179).  In an effort to assess the effect of KC deficiency on immune cell 
infiltration into the heart, we used immunohistochemical staining of sagittally 
bisected heart sections from WT or KC-/- mice on days 11 and 21 post-Bb 
infection.  We used F4/80 and RB6-8C5 to label macrophages and neutrophils, 
respectively.  Reflecting the results obtained using carditis severity and type 
scores (fig. 3.6), at day 11 post-infection, few immune cells were present in the 
hearts of WT or KC-/- mice.  By day 21 post-infection, WT hearts exhibited severe 
carditis that coincided with the presence of a large number of both macrophages 
and neutrophils (fig. 3.7).  KC-/- mice, however, displayed almost an almost 
complete absence of neutrophils in cardiac tissue, accompanied by a drastic 
reduction in the number of macrophages compared to WT mice at this time point  
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Fig. 3.6.  KC-/- mice have attenuated Lyme carditis and altered immune cell 
infiltration into Bb-infected heart tissue (134).  Sagittally bisected heart 
sections from 8 WT and 8 KC-/- mice at days 11 and 21 post-infection were 
stained with H&E and carditis severity (A) and type scores (B) were generated 
on a scale of 0 – 4.  Data shown are means ± SEM, and * indicates a significant 
difference from WT at the same time point (p <0.05).  Assessment of histological 
sections and determination of carditis severity and type scores was performed by 
Jennifer Hughes-Hanks. 
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Fig. 3.7.  KC-/- mice have significantly reduced numbers of neutrophils and 
macrophages in Bb-infected heart tissue (134).  Sagittally bisected heart 
sections were stained with the neutrophil marker RB6-8C5 (RB6) or the 
macrophage marker F4/80.  Representative sections from day 21 post-infection 
are displayed above.  Magnification X100.  Bar = 50µm.  Determination of heart 
pathology and cell infiltrate was conducted by Jennifer Hughes-Hanks. 
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(fig. 3.7).  This data indicated that KC mediated the recruitment of neutrophils 
and macrophages to Bb-infected cardiac tissue and was critical for the 
development of carditis.  
 
H. Bb clearance from heart tissue is intact in the absence of KC.   
 Neutrophils and macrophages are the main phagocytic cells responsible 
for the clearance of Bb from infected tissues (169-171, 179, 180).  As the 
presence of these cells in the infected cardiac tissue of KC-/- mice was greatly 
reduced (fig. 3.7), we hypothesized that the capacity to clear Bb from these 
tissues would be decreased.  Therefore, we used quantitative Real-Time PCR to 
assess the presence of Bb in the hearts of WT and KC-/- mice and days 10, 21, 
and 35 post-infection.  We found no differences in the quantity of Bb at any time 
point (fig. 3.8), indicating that although the numbers of neutrophils and 
macrophages in the hearts of KC-/- were reduced, this did not affect the ability of 
the mice to clear the infection.  
 
I. Heart cytokine and chemokine production is unaffected by the absence of 
KC.   
 Because neutrophil and macrophage numbers were decreased in the 
hearts of KC-/- mice concurrent with reduced carditis severity, we were curious as 
to how the cytokine milieu in the hearts of these mice would be affected.  
Therefore, we extracted protein from the hearts of WT and KC-/- mice 11 and 21  
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Fig. 3.8.  KC-/- mice are not defective in their ability to clear Bb infection 
from cardiac tissue (134).  Hearts were removed from mice at days 10, 21, and 
35 post-infection.  Spirochete DNA was detected in sagittally bisected heart 
tissue using quantitative Real Time PCR.  Copies of the Bb flagellin gene (FlaB) 
were normalized to 1000 copies of the mouse gene nidogen (Nido).  Data are 
representative of two separate experiments and bars indicate median values. 
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days post-Bb infection and assessed the production of pertinent cytokines via 
ELISA. 
 TNF-α, IL-1β, and IL-6 are all cytokines that are known to play important 
roles in the induction of inflammation.  As neutrophil numbers, macrophage 
numbers, and cardiac inflammation were reduced in the KC-/- mice, we 
postulated that the production of these cytokines would be reduced, as well.  
However, the expression of TNF-α, IL-1β, and IL-6 was no different in the hearts 
of KC-/- mice compared to WT mice (fig. 3.9 A), and indicated that these 
cytokines were not affected by the absence of KC signaling and were perhaps  
produced by cells other than F4/80+ macrophages or Gr-1+ neutrophils.  Notably, 
IL-6 was produced in 10-fold higher quantities in heart tissue than joint tissue 
(fig. 3.5 A) suggesting that this cytokine is regulated differentially based on 
tissue microenvironment. 
 LIX and MIP-2, like KC, are CXCR2 ligands important for inducing the 
chemotaxis of neutrophils and macrophages to sites of infection.  Because they 
share a common receptor and function similar to KC, it was possible that LIX and 
MIP-2 would be increased in an effort to compensate for the loss of KC in the KC-
/- mice.  However, the expression of these chemokines in the hearts of Bb-
infected mice at days 11 and 21 post-infection was unaffected by the loss of KC, 
as WT and KC-/- mice had equivalent levels of both LIX and MIP-2 at both time 
points (fig. 3.9 B).  This data indicated that LIX and MIP-2 were not upregulated 
in an effort to compensate for the loss of KC signaling in the KC-/- mice, indicating 
that KC signaling through CXCR2 was critical for the recruitment of neutrophils  
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Fig. 3.9.  Cytokine and chemokine levels in heart tissue of KC-/- mice are 
unaltered (134).  Hearts were removed on days 11 and 21 post-infection and 
protein was extracted.  Levels of the cytokines IL-6, IL-1β, and TNF-α (A) and the 
chemokines KC, LIX, and MIP-2 (B) were quantified using ELISA.  No significant 
differences were noted between KC-/- mice and WT mice at any time point. 
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and macrophages to both joint and heart tissue during Bb infection.  Interestingly, 
similar to what was seen with IL-6, it appears that differential tissue factors 
regulate the expression of LIX and MIP-2, as LIX was found in 10-fold higher 
quantities in the hearts of Bb-infected mice, while MIP-2 was found in 10-fold 
higher quantities in joint tissue. 
 
III. DISCUSSION 
 Neutrophils are known to play a significant role in the development of 
various models of arthritis (109, 161-166), as well as human Rheumatoid arthritis 
(RA) (167, 168), making neutrophil chemotactic factors attractive therapeutic 
targets (181-185).  However, strategies targeting chemotactic factors in a 
therapeutic manner have had limited success, as the mechanisms that mediate 
the recruitment of neutrophils to sites of inflammation are still unclear. 
 Lyme arthritis is a valuable model for the study of various arthritides 
including RA as it allows for the study of multiple phases of an arthritic immune 
response (induction, peak, and resolution) whereas many autoimmune (chronic) 
models only allow the study of the induction and peak. This is valuable in terms 
of therapeutic design, as it allows for the study of resolution mechanisms that 
have the potential to be induced, rather than simply dampening inflammation, as 
most current therapeutics do.  
 However, the immunological mechanisms regulating the development and 
severity of experimental Lyme disease are incompletely understood.  It was 
discovered early on that a genetic component is involved, as certain mouse 
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strains were susceptible to inflammation resulting from infection with Bb 
[(C3H/He, SWR, CB.17 (SCID)] while other strains appeared resistant (C57BL/6, 
BALB/c, SJL) independent of their susceptibility to infection (130, 131).  In 2003, 
Brown, et al. determined that the chemokines KC and MCP-1 were upregulated 
in genetically susceptible C3H/HeJ mice compared to resistant C57BL/6 mice 
and that while the absence of CCR2, the receptor for MCP-1, had no effect on 
disease severity, the absence of CXCR2, the receptor for KC, resulted in 
attenuated disease in susceptible C3H/HeJ mice.  This was the first study to 
definitively determine a difference in immunological mechanisms regulating 
disease susceptibility and proved, for the first time, that Lyme arthritis was 
mediated by the recruitment of neutrophils.  In the current study, we determined 
that the CXCR2 ligand KC was critical for the recruitment of neutrophils and in its 
absence the functionally similar CXCR2 ligands LIX and MIP-2 were unable to 
compensate for its loss.  Thus, KC signaling through CXCR2 alone mediated the 
recruitment of neutrophils to infected tissues and subsequent development of 
experimental Lyme arthritis. 
 Surprisingly, we determined that the KC/CXCR2 axis not only regulated 
the development of experimental Lyme arthritis, but carditis as well.  Neutrophils 
predominate during Lyme arthritis (130) while macrophages are the dominant cell 
type found in cardiac lesions (126, 135, 179).  As KC is a potent neutrophil 
chemoattractant, we hypothesized that, in its absence, neutrophils would be 
reduced in arthritic joint tissue and thus disease severity would be reduced.  
However, carditis in the KC-/- mice was also significantly reduced and this 
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reduction in severity was accompanied by an almost complete absence of 
neutrophils and a drastic reduction in macrophages in infected cardiac tissue.  
This information suggests that, although macrophages are the dominant cell type 
in cardiac tissue during Lyme carditis, neutrophils mediate the overall 
inflammatory response.  The mechanisms by which neutrophils mediate carditis 
are still unclear. 
 Interestingly, although numbers of neutrophils and macrophages were 
drastically reduced in joint and heart tissue, the ability to clear Bb was unaffected 
in the absence of KC.  In vitro, both neutrophils and macrophages are efficient at 
the phagocytosis and killing of Bb (179, 186, 187); however, the role of these 
cells in vivo is unclear.  It has been shown that susceptibility to the development 
of Lyme arthritis or carditis is independent of susceptibility to infection, as both 
susceptible and resistant strains harbor similar amounts of Bb (130).  The 
disparity between the development of disease and the ability to clear Bb infection 
remains unclear.  However, it has been suggested that current technologies are 
outdated and that the qPCR primers used to detect the presence of Bb in 
infected tissues are unable to distinguish between live and dead spirochetes.  If 
this is the case, it could be that although WT mice appear to have similar 
quantities of Bb in tissues compared to KC-/- mice, the DNA that is being detected 
is from killed Bb, indicating that there is indeed a defect in the ability of KC-/- to 
clear infection.  However, this possibility is purely speculation. 
 Many of the hypotheses developed in an effort to explain the failure of 
current therapeutics targeting chemokines are centered on the fact that the 
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chemokine system is highly redundant.  In 2003, Brown et al. discovered that in 
the absence of CXCR2 signaling, neutrophil recruitment was diminished and 
Lyme arthritis severity was attenuated.  Three chemokines, perhaps redundantly, 
signal through this receptor: LIX; MIP-2; and KC.  As KC was expressed more 
highly in susceptible mouse strains when compared to resistant mouse strains 
and KC-/- mice exhibited similar defects in neutrophil recruitment and arthritis 
severity, it is highly likely that KC signaling through CXCR2 mediates these 
effects.  Due to the possibly redundant nature of KC, LIX, and MIP-2, we 
hypothesized that the expression of LIX and MIP-2 might be increased in an 
effort to compensate for the loss of KC in KC-/- mice.  However, this did not 
appear to be the case, as LIX and MIP-2 were expressed at similar levels in the 
KC-/- mice as WT mice.  The fact that neutrophil recruitment was drastically 
reduced in the absence of KC suggests that, in the case of Lyme arthritis and 
carditis, LIX, MIP-2, and KC are not redundant in nature and that KC alone 
mediated the recruitment of neutrophils to sites of Bb infection via signaling 
through CXCR2. 
 Due to the fact that KC-/- mice exhibited fewer neutrophils and 
macrophages in infected hearts and joints, we hypothesized that the expression 
of cytokines would also be reduced in these mice.  We therefore looked at the 
expression of three cytokines known to be important in developing immune 
responses, especially arthritis (188-191), and found no differences in the 
expression of IL-6, TNF-α, or IL-1β at any time point.  These data suggest that 
neutrophils and macrophages were not the primary producers of these proteins 
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in joint and heart tissue and that these cytokines were not directly linked the 
development of Lyme arthritis or carditis.  These data may also suggest that 
although KC is important for the recruitment of neutrophils, it does not affect the 
activation of circulating neutrophils.  However, as these cytokines are important 
for the development of an immune response, the fact that their expression is 
unaltered may help to explain why these mice are able to effectively clear 
infection. 
 Prior to this study, the mechanisms regulating the development of Lyme 
arthritis and carditis were incompletely understood.  In combination with results 
obtained by Brown, et al., it is now well understood that the development of both 
Lyme arthritis and carditis is driven by neutrophil recruitment mediated by the 
KC/CXCR2 axis.   
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CHAPTER FOUR 
 
THE EFFECT OF CYCLOOXYGENASE-2 DEFICIENCY ON THE 
CYTOKINE/CHEMOKINE/LIPID MILIEU DURING LYME ARTHRITIS 
 
 
I. INTRODUCTION 
 Cyclooxygenase-2 (COX-2) has long been associated with inflammation 
as its expression is inducible and it is upregulated in immune cells during 
inflammation (25-27, 52, 53).  In 2002, Anguita, et al. reported that COX-2 mRNA 
expression correlated with the degree of arthritis severity associated with Bb-
induced Lyme arthritis and that specific inhibition of this enzyme resulted in 
reduced disease severity (140). However, in a similar experiment, Blaho, et al. 
found that specific inhibition of COX-2 (using Celecoxib-containing chow) in Bb-
infected mice did not result in the alleviation of arthritis severity (141).  At day 17 
post-infection, the peak of disease severity, mice fed control chow and mice fed 
Celecoxib-containing chow had similar disease severity.  Interestingly, on day 35 
post-infection, a time point at which control chow-fed mice had resolved arthritis, 
the joints of mice fed Celecoxib-containing chow remained severely inflamed 
(141).  Bb-specific antibody production (IgM and IgG) was intact in these mice 
and they were able to clear Bb from tissues as effectively as control chow-fed 
mice, suggesting that the defect in arthritis resolution was not due to an inability 
to mount an effective immune response and clear bacteria from tissue.  Results 
were similar whether mice were fed the Celecoxib-containing chow throughout 
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the entire course of infection or whether the chow was only fed to day 14 post-
infection indicating that early COX-2 metabolite production played an important 
role in the development of resolution mechanisms.  These results are consistent 
with the hypothesis presented by Drs. Charles N. Serhan and Bruce D. Levy 
suggesting that lipid mediators produced early during inflammation are 
responsible for programming resolution mechanisms (7, 82).  
 To determine the resolution mechanisms rendered defective by COX-2 
inhibition, we conducted a similar time course study in which mice were fed either 
normal mouse chow or Celecoxib-containing chow for two weeks prior to 
infection with Bb and the production of eicosanoids, cytokines, and chemokines 
was assessed.  Furthermore, we conducted three studies in which mice were 
treated with either prostaglandin J2 (PGJ2), PGE2, or an agonist to the 
prostaglandin E receptor 2 (EP2) to determine whether defective production of 
these metabolites was responsible for the lack of resolution seen during COX-2 
inhibition. 
 
II. RESULTS 
A. Inhibition of COX-2 results in attenuated ankle joint swelling, but has 
little effect on arthritis severity. 
 Mice (n = 30 per group) were fed a chow supplemented with 1000 ppm 
Celecoxib (equivalent to ~2 mg/kg (141)) or a normal chow diet (control mice) for 
two weeks prior to infection with 1 × 105 Bb.  Tibiotarsal (ankle) joint swelling was 
monitored throughout the course of disease and on days 0, 7, 14, 24, and 62 
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post-infection, mice were sacrificed and ankle joint tissues were collected for the 
analysis of arthritis severity, arthritis type scores, and tissue eicosanoid 
production.  Celecoxib-fed mice had significantly reduced joint swelling on days 
24, 34, 46, and 62 post-infection (fig. 4.1 A), indicating that metabolites produced 
via the COX-2 pathway were responsible for ankle joint swelling associated with 
Lyme arthritis.  Typically, joint swelling is indicative of underlying tissue 
inflammation; however, this is not always the case during experimental Lyme 
arthritis (153).  Although ankle swelling was reduced at most time points, arthritis 
severity was similar in Celecoxib-fed and control mice at all time points except for 
day 24 post-infection (fig. 4.1 B).  By day 62 post-infection, both Celecoxib-fed 
and control mice had fully resolved arthritis.  
 Arthritis type scores in this experiment were highly variable and thus 
difficult to analyze; however, the peak of arthritis severity in both Celecoxib-fed 
and control mice (days 14 - 24 post-infection) was characterized by a dominating 
presence of neutrophils at days 7, 14, and 24 post-infection, while the beginning  
(day 0 – 7 post-infection) and end (day 62 post-infection) of the immune 
response was characterized by an influx of macrophages (fig. 4.1 C).  Celecoxib-
fed mice exhibited no significant difference in infiltrating immune cells compared 
to control mice, suggesting that COX-2 inhibition does not directly affect immune 
cell recruitment during Lyme arthritis. 
  
  
 
65 
 
Fig. 4.1. Progression of arthritis in Celecoxib-fed mice.  30 mice were fed a 
chow supplemented with 1000 ppm Celecoxib and 30 mice were fed a normal 
chow diet as controls.  Mice were infected with 1 × 105 Bb and disease was 
allowed to progress for 62 days.  Throughout the course of disease, tibiotarsal 
joint (ankle) swelling was monitored using calipers (A).  On days 0, 7, 14, 24, and 
62 post-infection, 6 control and 6 Celecoxib-fed mice were sacrificed.  Arthritis 
severity (B) and type (C) was determined using histological samples as 
described in Methods & Materials.  Jennifer Hughes-Hanks performed 
histological assessment of pathology. *** = P < 0.001. 
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B. Inhibition of COX-2 affects the production of numerous eicosanoids. 
 To determine the effects of COX-2 inhibition on global eicosanoid 
production, we isolated lipids from ankle joint tissue of control and Celecoxib-fed 
mice on days 0, 7, 14, 24, and 62 post-infection.  Isolated lipid samples were 
sent to Dr. Darren S. Dumlao in Dr. Edward A. Dennis’ lab at the University of 
California – San Diego for analysis via LC-MS/MS. Fold increases or decreases 
in metabolite expression were compared and differences are shown on a heat 
map (fig. 4.2).  As expected, the expression of the majority of COX-derived 
metabolites were decreased in the Celecoxib-fed mice (e.g.: PGF1α, PGF2α, 
PGE2, PGD2).  Largely, lipoxygenase (LOX) metabolites were unaffected, 15-
LOX metabolites exhibited mild reductions in expression (15-HETE), and 12-LOX 
metabolites exhibited both increases (9-HODE) and decreases (12-HETE) in 
expression.  Metabolites generated via the cytochrome P450 (CYP) pathway, 
including 18-HEPE, 17,18-EpETE, 9.10-EpOME, and 12,13-EpOME were 
generally increased in Celecoxib-fed mice.  These results indicate that COX-2 
inhibition dynamically affects the production of several eicosanoids and that 
these effects are not limited to the COX-2 pathway. 
 
C. COX-2 metabolites are reduced in mice fed Celecoxib-containing chow. 
 The LC-MS/MS-generated heat map indicated reductions in the COX-2 
metabolites PGE2, 6k-PGF1α, and 11-HETE upon COX-2 inhibition (fig. 4.2).  To 
further analyze these reductions, we calculated the amounts of these 
eicosanoids in picograms per milligram of joint tissue (fig. 4.3).   
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Fig. 4.2. Global eicosanoid production in Celecoxib-fed mice.  Lipids were 
extracted from ankle joint tissue of mice fed either a normal chow diet (control) or 
a diet supplemented with Celecoxib on days 0, 7, 14, 24, and 62 post-infection 
with Bb.  Eicosanoids were quantified via LC-MS/MS.  Values shown represent 
fold change in metabolite production in the Celecoxib-fed mice compared to 
control mice at the same time point.  A red color indicates a fold increase in 
metabolite production and a green color indicates a fold decrease in metabolite 
production.  (LC-MS/MS analysis and construction of heat map conducted by Dr. 
Darren S. Dumlao, UCSD.) 
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Although the heat map indicated that PGE2 was reduced four-fold in the 
Celecoxib-fed mice on days 14 and 24 post-infection (fig. 4.2), this reduction did 
not reach statistical significance (fig. 4.3 A).  However, the reduced PGE2 
expression at these time points may explain the reduced swelling in the 
Celecoxib-fed mice, as PGE2 is a known mediator of swelling due to its effects on 
vascular permeability and edema formation (192).  6k-PGF1α is a stable 
breakdown product of the COX-1 metabolite PGI2, which serves as a potent 
vasodilator (193).  Production of this metabolite was reduced two-fold (fig. 4.2), 
but once again this reduction did not reach statistical significance (fig. 4.3 B).  
11-HETE is implicated to be anti-inflammatory and was significantly reduced at 
day 7 post-infection in the Celecoxib-fed mice compared to control mice (fig. 4.2 
C).  The reduction in this metabolite may suggest a mechanism by which COX-2 
inhibition prolongs the inflammatory state of arthritic mice (141). 
 
D. Lipoxygenase (LOX) metabolites are differentially affected by COX-2 
inhibition. 
 COX-2 inhibition had differential effects on metabolites production via the 
three lipoxygenase pathways.  5-HETE, a metabolite produced via the 5-LOX 
pathway, was unaffected by COX-2 inhibition (fig. 4.4 A).  However, 15-HETE, 
produced via the 15-LOX pathway, and 12-HETE and HXB3, produced via the 
12-LOX pathway, were all significantly reduced on day 7 post-infection (fig. 4.4 B 
- D).   
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Fig. 4.3. Production of cyclooxygenase-derived metabolites in the ankle 
joints of Celecoxib-fed mice.  Lipids were extracted from the ankle joints of 
control and Celecoxib-fed mice on days 0, 7, 14, 24, and 62 post-infection with 
Bb.  Quantities of PGE2 (A), 6k-PGF1α (B), and 11-HETE (C) were detected 
using LC-MS/MS.    * = P < 0.05.  (LC-MS/MS performed my Dr. Darren S. 
Dumlao.)
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Fig. 4.4. Production of lipoxygenase metabolites in the ankle joints of 
Celecoxib-fed mice.  30 mice were fed a normal chow diet and 30 mice were 
fed a diet supplemented with Celecoxib.  Mice were infected with Bb and disease 
was allowed to progress for 62 days.  On days 0, 7, 14, and 24 post-infection, 
lipids were extracted from ankle joint tissue of mice and the lipoxygenase 
metabolites 5-HETE (A), 15-HETE (B), 12-HETE (C), and HXB3 were detected 
using LC-MS/MS.  * = P < 0.05.  *** = P < 0.001.  (LC-MS/MS analysis was 
conducted by Dr. Darren S. Dumlao.) 
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As both the 12- and 15-LOX pathways are involved in pro-resolving lipoxin 
production and COX-2 inhibition appeared to negatively impact the production of 
metabolites produced via these pathways, it is possible that COX-2 inhibition 
interferes with pro-resolution pathway.  This could potentially explain the 
defective resolution of arthritis in Celecoxib-treated mice observed by Blaho, et 
al. (141). 
 The fact that the eicosanoid data were so variable and often did not reach 
statistical significance is likely due to a low sample size. Only three joints were 
available for eicosanoid analysis per time point.  A repeat of this experiment with 
a larger sample size is needed in order to better ascertain the effects of COX-2 
inhibition on eicosanoid production.  A power analysis would be an effective tool 
for the determination of a sample size that would adequately provide useful 
results. 
 
E. Supplementation of COX-2-/- mice with PGJ2 does not restore the ability 
to resolve arthritis. 
 Similar to the phenotype observed in Celecoxib-fed mice, Blaho, et al. 
observed that mice deficient in COX-2 (COX-2-/-) were unable to resolve Lyme 
arthritis (141).  15 deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is a stable 
breakdown product of PGD2.  It is reportedly anti-inflammatory as, in vitro, it 
binds the nuclear receptor PPARγ and inhibits NF-κB activation (65-68).  COX-2-
/- mice and mice treated with the COX-2 inhibitor Celecoxib have reduced levels 
of both PGD2 and 15d PGJ2 ((144) and fig. 4.2).  Thus, we hypothesized that 
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treatment of COX-2-/- mice with 15d-PGJ2 on days 3-14 post-infection may 
restore the ability to resolve arthritis in these mice.  Treatment of mice with 15d-
PGJ2 on days 3-14 was decided based on the fact that COX-2 inhibition early 
during infection (day -1 through day 14 post-infection) resulted in inhibition of 
resolution, indicating that metabolites produced via this pathway early during 
inflammation were responsible for inducing subsequent resolution (141).  We 
infected 10 wild type (WT) C3H/HeJ and 10 C3H COX-2-/- with 1 × 105 Bb.  Five 
WT and 5 COX-2-/- mice were subcutaneously treated with 50-µL vehicle PBS 
and 5 WT and 5 COX-2-/- mice were treated with 60 µg 15d PGJ2 in 50 µL PBS.  
Disease was allowed to progress for 35 days and ankle swelling was monitored 
throughout the course of disease.   
 Although ankle swelling was slightly reduced in COX-2-/- mice as 
compared to WT mice, this trend did not reach statistical significance (fig. 4.5 A).  
Furthermore, treatment of COX-2-/- mice with 15d PGJ2 did not affect the ankle 
swelling in these mice compared to COX-2-/- mice treated with PBS (fig. 4.5 B).  
Although the data from this study suggest that 15d PGJ2 does not affect ankle 
swelling in COX-2-/- mice, some major flaws in the experimental design of this 
study are apparent: 1) the goal of the study was to assess the affect of 
supplementation with 15d-PGJ2 on arthritis resolution, not ankle joint swelling.  
Thus, it would have been much more effective to conduct this study with time 
points at which arthritis severity was assessed rather than simply monitoring 
ankle swelling.  2) Ankle swelling is not always indicative of underlying 
inflammation.  Although no effects were seen on the progression of ankle  
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Fig. 4.5. 6k-PGJ2 treatment of COX-2-/- mice.  10 WT mice and 10 COX-2-/- 
mice were infected with Bb.  5 WT and 5 COX-2-/- mice were treated 
subcutaneously with PBS and 5 WT mice and 5 COX-2-/- mice were treated with 
60 µg 15d-PGJ2 on days 3-14 post-infection.  Ankle joint swelling was monitored 
using metric calipers for 35 days. 
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swelling in these mice, the underlying immune response could have been 
affected.  Once again, this would suggest that assessing arthritis severity via 
histology would have been more effective.  3) Eicosanoids are bioactive and 
insoluble in most vehicles (including PBS in most instances).  Although PBS was 
originally selected as a vehicle due to its inert qualities, it is possible that 15d-
PGJ2 was unable to effectively solubilize in PBS.  It is also possible that 15d-
PGJ2, due to its bioactive nature, degraded prior to being able to exert any 
biological effects.  A more effective route may have been intravenous or 
intraperitoneal injection and a more effective vehicle may have been ethanol or 
methyl acetate (diluted in PBS).  
 
F. Supplementation of COX-2-/- mice with PGE2 does not restore the ability 
to resolve arthritis. 
 PGE2 is believed to mediate the “switch” from pro-inflammatory eicosanoid 
production to anti-inflammatory eicosanoid production by reducing the expression 
of 5-LOX and LTB4 production and increasing 15-LOX expression and 15-HETE 
(and subsequent LXA4) production (82).  As PGE2 production was reduced in 
Celecoxib-fed and COX-2-/- mice, we hypothesized that the absence of this 
eicosanoid might be responsible for defective resolution of Lyme arthritis in these 
mice.  Therefore, we performed an add-back experiment to restore PGE2 levels 
in COX-2-/- mice infected with Bb and determined the effect that this had on 
arthritis resolution.  Ten WT mice and 12 COX-2-/- mice were infected with 1 × 
105 Bb and either treated with PBS (vehicle) or 1.0-µg of PGE2.  Mice were 
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treated via daily subcutaneous inoculations in the scruff of the neck throughout 
the course of infection.  The infection was allowed to progress for 35 days, after 
which mice were sacrificed and ankle joint tissues were collected for the 
assessment of arthritis severity.  We found that ankle joint arthritis severity in the 
COX-2-/- mice was similar to that of WT mice whether treated with PGE2 or not 
(fig. 4.6).  It is worth noting, however, that in contrast to defective resolution seen 
previously in these COX-2-/- mice, the COX-2-/- mice treated with PBS had 
equivalent severity scores compared to WT mice treated with PBS at day 35 
post-infection.  This could indicate that the infection was not as effective as that 
completed by Blaho, et al. (as a result of different passages of Bb, ineffective 
infection, etc).  Furthermore, the same issues discussed in regards to the 15d-
PGJ2 treatment are present in this study, as well: the route of treatment 
(subcutaneous) and the vehicle (PBS) may not have been ideal of effective 
delivery of PGE2. 
 In order to better assess the effect of PGE2 on the resolution of Lyme 
arthritis, we decided to directly target specific PGE2 receptors.  The EP2 and EP4 
receptors are known to mediate many of the inflammatory effects of PGE2 (91, 
194-197).  In an effort to bypass the risk of PGE2 degrading prior to activating its 
receptor, we decided to utilize the stable EP2 agonist, Butaprost.  Ten WT and 8 
COX-2-/- mice were infected with 1 × 105 Bb.  2 WT were left untreated, 4 WT and 
4 COX-2-/- mice were treated with vehicle (dilution of ethanol in PBS), and 4 WT 
and 4 COX-2-/- mice were treated with 5-µM Butaprost dissolved in 100-µL PBS.  
Treatments were delivered intraperitoneally on days 5 – 7 post-infection and  
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Fig. 4.6. Treatment of COX-2-/- mice with PGE2.  10 WT and 12 COX-2-/- mice 
were infected with 1 × 105 Bb.  5 WT and 6 COX-2-/- were treated subcutaneously 
with PBS and 5 WT and 6 COX-2-/- mice were treated with 1.0-µg PGE2 daily 
throughout the course of infection.  On day 34 post-infection, mice were 
sacrificed and ankle joints were collected, fixed, mounted, and stained using H & 
E.  Arthritis severity was assessed histologically by Jennifer Hughes-Hanks. 
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days 12 – 15 post-infection, the time points at which PGE2 expression peaks 
during Bb infection in WT mice (143).  Disease was allowed to progress for 42 
days, after which mice were sacrificed and tissues were collected for the 
histological assessment of joint tissue severity.  As previously reported by Blaho, 
et al. (141), COX-2-/- mice treated with PBS had increased joint severity as 
compared to WT mice treated with PBS or left untreated, indicating that as of day 
42 post-infection, COX-2-/- mice were unable to resolve Lyme arthritis (fig. 4.7).  
However, mice treated with Butaprost had arthritis that was comparable to WT 
mice, indicating that stimulation of the EP2 receptor in COX-2-/- mice enabled 
these mice to resolve Lyme arthritis.  These data suggest that PGE2 signaling 
through the EP2 receptor mediates the resolution of Lyme arthritis and that 
inhibition of COX-2 disrupts this process.  However, caution should be had when 
interpreting these results as this experiment has only been conducted 
successfully one time due to the limited availability of COX-2-/- mice. 
 
G. Cytokine and chemokine production is reduced in COX-2-/- mice. 
 Although the lack of resolution of Lyme arthritis observed during COX-2 
inhibition was likely due to the effects on the eicosanoid microenvironment, 
downstream effects on other immune pathways are likely playing a role, as well.  
As eicosanoids are known to be involved in the regulation of cytokine and 
chemokine production (often due to effects on NF-κB), we wanted to assess 
whether any pertinent cytokines or chemokines were affected during COX-2 
inhibition.  Therefore, 30 mice were fed a chow supplemented with 1000 ppm  
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Fig. 4.7.  Treatment of COX-2-/- mice with the EP2 agonist Butaprost.  10 WT 
mice and 8 COX-2-/- mice were infected with 1 × 105 Bb.  2 WT mice were left 
untreated, 4 WT mice were treated with PBS, and 4 WT mice were treated with 
5-µM Butaprost.  4 COX-2-/- mice were treated with PBS and 4 COX-2-/- mice 
were treated with 5-µM Butaprost.  Disease was allowed to progress for 42 days.  
On day 42 post-infection, ankle joint tissues were collected, fixed, mounted, and 
stained with H & E for histological assessment of arthritis severity.  Histological 
assessment of pathology performed by Jennifer Hughes-Hanks.  * = P < 0.05. 
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Celecoxib and 30 mice were fed a normal chow diet (control mice) for two weeks 
prior to infection with 1 × 105 Bb.  On days 0, 7, 14, 24, and 62 post-infection, 
mice were sacrificed and tissues were collected for the quantification of TNFα, IL-
6, IL-10, and KC production via ELISA.  All cytokines trended lower at all time 
points in the Celecoxib-fed mice compared to WT mice (fig. 4.8).  TNFα and IL-
10 were significantly reduced at the peak of infection, day 24 post-infection (fig. 
4.1 B, fig. 4.8 A).  The effects of COX-2 metabolites on these two cytokines are 
often dependent on the concentration of metabolite present (or administered, in 
the case of in vitro experiments), but studies have shown that PGE2 is able to 
inhibit TNFα production and induce IL-10 production (198-201).  As TNFα and IL-
10 were only affected mildly and only on day 24 post-infection, it could be that 
the mild reduction in PGE2 production observed in the Celecoxib-fed mice (fig. 
4.3 A) was sufficient to have a negative impact on the production of these 
cytokines.  The production of IL-6 is highly regulated by COX-2-derived 
metabolites (202-205) and its production was significantly reduced at every time 
point analyzed in Celecoxib-fed mice (fig. 4.8 B).  KC, which is required for the 
development of Lyme arthritis (134), was significantly reduced on days 7 and 14 
post-infection (fig. 4.8 D).   
 Similarly, we assessed the production of TNFα, IL-12p70, IL-1β, and KC in 
COX-2-/- mice.  In order to do this, we infected 4 WT and 4 COX-2-/- mice with 1 × 
105 Bb and allowed disease to progress to day 24 post-infection (the peak of 
severity, fig. 4.1 B).  Throughout the course of infection, ankle swelling was 
monitored.  On day 24 post-infection, ankle joint tissue was extracted and  
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Fig. 4.8.  Cytokine and chemokine production in the ankle joints of 
Celecoxib-fed mice.  30 mice were fed a normal chow diet and 30 mice were 
fed a diet supplemented with 1000 ppm Celecoxib.  Mice were infected with Bb 
and disease was allowed to progress for 62 days.  On days 0, 7, 14, 24 and 62 
post-infection, ankle joint tissue was extracted and quantities of TNFα (A), IL-6 
(B), IL-10 (C), and KC (D) were detected using ELISA and normalized to total 
protein concentration quantified using BCA.  ** = P < 0.01.  *** = P < 0.001. 
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cytokines/chemokines were quantified using ELISA.  As previously observed, 
COX-2-/- mice exhibited reduced ankle joint swelling compared to WT littermates 
(fig. 4.9 A).  Furthermore, all of the cytokines/chemokines assessed trended 
lower in the COX-2-/- compared to WT littermates (fig. 4.9 B – E).  Although 
statistical significance was not reached in these assays, it is possible that if more 
mice were included in the sample size, significance would be achieved. 
 These studies indicate that along with effects on eicosanoid production, 
inhibition of COX-2 results in diminished cytokine/chemokine production.  As 
many eicosanoids produced via the COX-2 pathway are known to induce 
cytokine production [e.g.: PGE2 induces IL-6 and IL-10 production (203, 206-
208)], it is possible that the reduced production of cytokines resulted from the 
reduced production of COX-2-derived eicosanoids. 
 
III. DISCUSSION 
 This study highlights the effects of COX-2 inhibition on the mechanisms 
involved in the progression and resolution of Lyme arthritis.  Previously, It was 
shown that inhibition of COX-2 results in the inability of mice infected with Bb to 
resolve arthritis (141).  This study indicated that COX-2 inhibition affects the 
function of numerous biosynthetic pathways and the production of cytokines and 
chemokines.  However, agonism of the PGE2 receptor EP2 using Butaprost 
appeared to effectively restore resolution to WT levels in COX-2-/- mice, 
suggesting that disruption of this pathway via COX-2 inhibition is responsible for 
defective resolution mechanisms. 
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Fig. 4.9.  Cytokine and chemokine production in COX-2-/- mice.  4 WT mice 
and 4 COX-2-/- mice were infected with Bb.  Disease was allowed to progress for 
24 days, during which time ankle swelling was monitored using metric calipers 
(A).  On day 24 post-infection, ankle joint tissue was collected and TNFα (B), IL-
1β (C), KC (D), and IL-12p70 (E) expression was quantified using ELISA and 
normalized to total joint protein quantified using BCA.  ** = P < 0.01. 
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 It is important to note that the study presented here, in which arthritis 
severity, eicosanoid production, and cytokine and chemokine production were 
monitored throughout the course of Lyme arthritis in mice fed a diet 
supplemented with Celecoxib, had methods and results that differed in significant 
ways from those conducted and reported by Blaho, et al. (141).  For example, in 
the study by Blaho, et al., mice fed the Celecoxib diet failed to resolve arthritis by 
day 35 post-infection.  However, in the study presented here, by day 62 post-
infection, Celecoxib-fed mice had fully resolved arthritis.  In fact, by day 24 post-
infection, severity was significantly reduced in Celecoxib-fed mice when 
compared to controls.  It is possible that if a time point was taken at day 35 post-
infection arthritis severity would be similar in Celecoxib-fed and control mice, as 
described by Blaho, et al.  If so, it would suggest that Celecoxib does not prevent 
the resolution of arthritis, but delays it.  Furthermore, in the study by Blaho, et al., 
feeding of the experimental diet started on day -1 of Bb infection.  However, in 
the study presented here, feeding of the experimental diet began 2 weeks prior to 
infection with Bb.  It is possible that extending the regimen of Celecoxib resulted 
in activation of compensatory mechanisms that this resulted in different findings. 
 It is intriguing that although severity and type scores were unaltered in the 
Celecoxib-fed and COX-2-/- mice during the peak of severity, the expression of 
several powerful cytokines and chemokines was reduced.  Although type scores, 
which measure immune cell infiltration, were also unaltered, it is possible that the 
immune response mounted in the absence of COX-2 was phenotypically different 
compared to the immune response in control animals.  Eicosanoids are known to 
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play important roles in the recruitment and activation of immune cells, and as 
COX-2 inhibition dynamically affected the production of eicosanoids, it is likely 
that the recruitment and activation of the subsequent immune response was 
affected as well.  Although macrophages and neutrophils were recruited during 
the immune response to Bb in the Celecoxib-fed or COX-2-/- mice similar to 
control and WT mice, alterations in the eicosanoid milieu may have impacted the 
activation of these cells and subsequent cytokine and chemokine production, 
explaining the effects seen in figures 4.8 and 4.9. 
 Further studies are required to clarify the exact mechanisms that are 
involved in the immune response during COX-2 inhibition.  It would be beneficial 
to repeat the Celecoxib experiment with more mice.  Furthermore, in order to 
translate results, it would be beneficial to start treatment one day prior to infection 
with Bb similar to the studies conducted by Blaho, et al.  Repeating the studies in 
which COX-2-/- mice are used would also be beneficial, especially if more mice 
were available and if a time course was possible.  Lastly, as the treatment of 
COX-2-/- mice with Butaprost appeared to enable these mice to resolve arthritis, it 
would be valuable to repeat this experiment to see if these results were 
repeatable.  If so, it could be confirmed that the PGE2/EP2 axis is responsible for 
resolution during Lyme arthritis. 
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CHAPTER FIVE 
 
THE EFFECT OF DIETARY FISH OIL SUBSTITUTION ON EXPERIMENTAL 
LYME DISEASE 
 
I. INTRODUCTION 
 Eicosanoids are derived from polyunsaturated fatty acids (PUFA) and are 
involved in many biological processes (209) including the modulation of both 
innate and adaptive immunity.  Eicosanoids are generated when PUFA are 
liberated from membrane phospholipids via phospholipase A2 (PLA2) and 
metabolized via a variety of enzymes, most notably the cyclooxygenases (COX-1 
and COX-2) and the lipoxygenases (5-, 12-, and 15-LOX).   
 A traditional Western diet results in the majority of dietary fatty acids (FA) 
being derived from ω-6 PUFA, including arachidonic acid (AA) and linoleic acid 
(LA).  Growing evidence suggests that incorporation of ω-3 FA derived from fish 
oil (FO) into the diet may be beneficial for the alleviation of a variety of immune 
disorders including cardiovascular disease, diabetes, rheumatoid arthritis, cystic 
fibrosis, and cancer (81, 210-214).  However, the mechanism by which FO 
mediates its beneficial effects remains unclear.  As eicosanoids derived from FO 
are less bioactive than their ω-6-derived counterparts, it is suggested that the 
substitution of FO-derived FA into membrane phospholipids results in a less anti-
inflammatory microenvironment (215-219).  Recent data also suggests that FO-
derived FA can directly inhibit inflammation-inducing mechanisms such as NF-
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κB-induced inflammasome activation and inducible nitric oxide synthase (iNOS) 
expression (220, 221). 
 We have previously used a high-throughput methodology to detect the 
temporal production of 139 eicosanoids throughout the course of experimental 
murine Lyme arthritis (144, 145).  AA-derived eicosanoids are known to play a 
role in the development and resolution of Lyme arthritis (fig. 5.1) and 
inflammation resulting from Bb infection is commonly treated with COX-2-specific 
non-steroidal anti-inflammatory drugs (NSAIDs) (222).  As FO-derived 
eicosanoids are believed to dampen inflammation, we wanted to assess the 
effects of dietary FO substitution on inflammation resulting from infection with Bb.  
Therefore, in the present study, we developed a diet in which ω-6-containing soy 
oil (SO, the FA source in typical murine diets) was replaced with ω-3-containing 
Menhaden fish oil and assessed the effects of this substitution on eicosanoid 
generation and Lyme arthritis and carditis severity. 
 
II. RESULTS 
A. Dietary fish oil substitution alters the serum and liver fatty acid profile. 
 To determine the effect of dietary fish oil substitution on total fatty acid 
(FA) composition, we constructed a rodent chow diet in which Menhaden fish oil 
was the primary source of fatty acids (FO diet).  Control animals were fed a 
normal chow diet in which soy oil was the primary source of fatty acids (SO diet).  
After two weeks, the serum and liver fatty acid composition of mice fed either the 
FO or SO diets was determined (Table 5.1).  The ω-6 fatty acids arachidonic  
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Fig. 5.1. Eicosanoids regulate all phases of Lyme arthritis (144).  Pro-
inflammatory cyclooxygenase (COX)-2-derived prostaglandins (PGs) such as 
PGE2 and PGD2 initiate the immune response to Bb while 15d-PGJ2 limits the 
severity of subsequent inflammation.  Lipoxygenase (LOX)-derived hepoxylin B3 
(HXB3) and leukotrienes (LTs) mediate the recruitment of neutrophils and 
mononuclear cells to sites of infection.  The production of DHA-derived protectins 
mediates the resolution of inflammation.  This information is based on a lipidomic 
analysis of the temporal production of eicosanoids throughout the course of 
Lyme arthritis detected using LC-MS/MS conducted by Blaho, et al. 2009 (144).  
(Figure generated by Dr. Victoria A. Blaho.) 
89 
 
 
Table 5.1. Dietary fish oil substitution alters the serum and liver fatty acid 
profile (145).  Mice were fed either a control diet in which fatty acids (FA) were 
derived from soy oil (SO) or a diet in which Menhaden fish oil was the primary 
fatty acid source (FO).  After two weeks on the diets, serum and liver fatty acids 
were determined by Dr. Kevin L. Fritsche.  Values represent mean ± SEM, n = 10 
mice.  * denotes that concentration of FA in the FO-fed mice differs significantly 
from concentration of FA in the SO-fed mice within individual tissues, p < 0.05.  
Fatty acids that constituted less than 0.5% of total fatty acids were not included 
on this table. (Values obtained and calculated and table constructed by Dr. Kevin 
L. Fritsche.) 
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acid (AA) and linoleic acid (LA) were the major fatty acids found in the serum and 
liver of SO diet-fed mice, with no traces of the fish oil-derived ω-3 fatty acids 
eicosapentaenoic acid (EPA) or docosapentaenoic acid (DHA).  When mice were 
fed the FO diet, serum and liver fatty acids were mainly comprised of EPA and 
DHA and levels of AA and LA were decreased.  This data indicated that feeding 
mice a diet in which FO is the primary FA source for two weeks led to alterations 
in the total fatty acid profile, as production of ω-6 fatty acids was significantly 
reduced and ω-3 fatty acids comprised the majority of total fatty acids. 
 
B. Dietary fish oil substitution alters global eicosanoid production. 
 To determine the effect of fish oil substitution on arthritic inflammation, we 
fed mice the SO or FO diets for two weeks prior to infecting them with Bb.  On 
days 0, 10, and 21 post-infection, we isolated lipids from joint tissue and 
characterized the production of 103 distinct eicosanoid species using LC-MS/MS 
(Table 5.2) (144).  At day 0, eicosanoid production did not differ between SO- 
and FO-fed mice.  However, as the infection progressed, metabolite production 
varied significantly.  The production of 30 metabolites was different between SO- 
and FO-fed mice at day 10 post-infection and production of 76 metabolites varied 
between the two diets day 21 post-infection. 
 To better visualize the changes in eicosanoid species produced 
throughout infection in either diet, we constructed a heat map displaying fold 
change in eicosanoid concentrations relative to day 0 (fig. 5.2 A).  In SO-fed 
mice, AA- and LA-derived metabolites increased up to 4-fold throughout 
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Table 5.2.  Dietary fish oil substitution results in a global shift in eicosanoid 
production (145).  Table displays total eicosanoid concentrations in the joints of 
soy oil (SO)- or fish oil (FO)-fed mice at 0, 10, and 21 days post-infection.  n = 4 
at days 0 and 10 and 9 at day 21 post-infection.  Values are total eicosanoid 
concentration (ng / mg tissue) ± SEM.  # denotes that a value is significantly 
different from day 0 within a diet while * denotes a significant difference in 
eicosanoid concentration between the SO and FO diet at a certain time point.  p 
< 0.05.  (Eicosanoid concentrations determined and table constructed by Dr. 
Darren S. Dumlao.) 
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Fig. 5.2.  Dietary fish oil substitution results in a global shift in eicosanoid 
generation (145).  Heat map displays the relative fold change of select AA-, LA-, 
EPA-, and DHA-derived eicosanoids in the joints of SO- or FO-fed mice at days 
0, 10, and 21 post-infection.  Eicosanoids are grouped based on subclass.  (A) 
Fold change in eicosanoids compared to day 0 in SO- or FO-fed mice.  For 
eicosanoids that were ND on day 0, the relative fold change was determined 
from the day that they first were detected.  (B) Comparison of the relative 
eicosanoid concentrations detected in FO-fed mice versus SO-fed mice.  ND 
(black) indicates that an eicosanoid was either not detected or was detected in 
concentrations below the limit of detection.  n = 4 at days 0 and 10 post-infection 
and 9 at day 21 post-infection.  (Heat map composed by Dr. Darren S. Dumlao.)
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 the course of infection, while EPA- and DHA-derived metabolites remained 
relatively unchanged.  In FO-fed mice, increases in AA- and LA-derived 
metabolites were not nearly as significant (1.5 – 2-fold on average), while EPA- 
and DHA-derived metabolites increased up to 4-fold throughout the course of 
infection.  That data suggested that FO substitution led to a drastic increase in 
the production of EPA- and DHA-derived metabolites and decreased production 
of AA- and LA-derived metabolites. 
 To more directly visualize the effect of the FO diet on eicosanoid 
production, we constructed a heat map showing relative fold change in 
eicosanoid production in mice fed the FO diet relative to those fed the SO diet 
(fig. 5.2 B).  We found that FO substitution led to a global shift in eicosanoid 
production, from AA- and LA-derived metabolites to EPA- and DHA-derived 
metabolites.  Expression of most EPA- and DHA-derived metabolites were 
increased approximately 4-fold over levels found in the SO-fed mice and the 
majority of AA- and LA-derived metabolites were significantly decreased when 
mice were fed the FO diet compared to those fed the SO diet.  At day 10 post-
infection, EPA- and DHA-derived metabolites accounted for approximately 47% 
of eicosanoids produced in the FO-fed mice, compared to 11% in the SO-fed 
mice.  At day 21 post-infection, the effect of FO substitution was even more 
apparent, as EPA- and DHA-derived metabolites accounted for approximately 
59% of total eicosanoids produced, compared to only 9% in the SO-fed mice.  
This data indicated that FO substitution led to a global shift in eicosanoid 
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production and that the majority of eicosanoid species produced in FO diet-fed 
mice were derived from EPA and DHA. 
 
C. Mono-hydroxylated fatty acid metabolites are produced primarily non-
enzymatically irrespective of diet. 
 AA-derived mono-hydroxylated metabolites (MHM) (HETEs) are 
vasoconstrictive and induce the development of edema (223).  EPA- and DHA-
derived MHM (HEPEs and HDoHEs) are precursors to the anti-inflammatory E-
series and D-series resolvins, respectively (224, 225).  Thus, AA-derived MHM 
are considered pro-inflammatory while EPA- and DHA-derived MHM are 
considered anti-inflammatory, suggesting another mechanism by which FO-
derived FA may induce an anti-inflammatory microenvironment. 
 We found that AA-derived MHM were increased, albeit to low levels, in 
SO-fed mice throughout the course of Bb infection (shown: 5-HETE, fig. 5.3), but 
were decreased in comparison in the FO-fed mice by day 21 post-infection.  
EPA-derived MHM (shown: 5-HEPE) and DHA-derived MHM (shown: 4-HDoHE) 
were found at low levels throughout the course of Bb infection in SO-fed mice, 
but were dramatically increased in comparison in the FO-fed mice at days 10 and 
21 post-infection.  These data suggested that EPA and DHA were the preferred 
substrates for 5-LOX for the production of MHM in the FO-fed mice. 
 MHM are unique in that they can be produced by two distinct 
mechanisms: enzymatically by lipoxygenases (LOX) or cytochrome p450 mono- 
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Fig. 5.3.  Dietary fish oil substitution results in increased levels of EPA- and 
DHA-derived mono-hydroxylated metabolites (MHM) (145).  Quantitative 
amounts of representative MHM produced in SO- or FO-fed mice throughout the 
course of Bb infection.  Values of AA-derived 5-HETE, EPA-derived 5-HEPE, and 
DHA-derived 4-HDoHe are means ± SEM.  n = 4 on days 0 and 10 post-infection 
and 9 on day 21 post-infection.  # denotes a significant difference from day 0 
within each diet and * denotes a significant difference in the concentrations of the 
eicosanoid in the FO-fed mice compared to the SO-fed mice.  p < 0.05.  
(Quantification of eicosanoids and construction of figure by Dr. Darren S. 
Dumlao.) 
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oxygenase-1 (CYP1) (224, 226) or non-enzymatically by reactive oxygen species 
(ROS) (227-229).  In order to determine the contribution of non-enzymatic 
mechanisms to the generation of MHM, we performed chiral LC-MS analysis.  
Enzymatic metabolism of fatty acids results in the production of metabolites in 
the S-isomeric state, while non-enzymatic metabolism yields a racemic (1:1) 
mixture of R- and S-isomers.  EPA- and DHA-derived R and S isomers were 
produced at ratio of 1:1, indicating that these metabolites were being produced 
primarily via non-enzymatic mechanisms (fig. 5.4).  The most abundant MHM 
produced, LA-derived 9- and 13-hydroxyoxtadecadienioc acid (9- and 13-HODE), 
were also found in a racemic mixtures, indicating that the majority of AA-, LA-, 
EPA-, and DHA-derived MHM were being produced as a result of non-enzymatic 
metabolism, perhaps as a result of ROS generated in response to Bb infection. 
 When we assessed the production of metabolites produced solely by non-
enzymatic mechanisms, we found that the total amounts of non-enzymatically 
produced metabolites were increased in the FO-fed mice at day 10 and 21 post-
infection (Table 5.3).  Further, the majority of non-enzymatically produced 
metabolites were derived from either EPA or DHA, suggesting that these fatty 
acids are more susceptible to oxidative stress than AA or LA.  Notably, 
isoprostanes, which are notorious for generation via non-enzymatic mechanisms 
(230, 231), were found at low levels regardless of diet, suggesting that they were 
produced primarily via cyclooxygenase (COX). 
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Fig. 5.4. The majority of mono-hydroxylated metabolites produced in fish 
oil-fed mice are generated non-enzymatically (145).  Representative chiral 
LC-MS/MS-generated chromatograph of MHM produced in the joint of a FO-fed 
mouse at day 21 post-infection.  Proper elution times were determined using 
commercially available standards for the R- and S-isomers of the individual 
eicosanoids.  Data is representative of 5 replicate samples.  (LC-MS/MS 
conducted and chromatograph generated by Dr. Darren S. Dumlao.) 
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Diet Soy Oil Fish Oil 
Day 0 10 21 0 10 21 
n 4 4 9 4 4 9 
Eicosanoid       
5-iso-PGF2α VI 0.2 ± 0.1 0.7 ± 0.1 1.2 ± 0.1 0.4 ± 0.1 0.8 ± 0.3 0.7 ± 0.1 
8-iso-PGF2α III 0.2 ± 0.1 0.4 ± 0.1 1.0 ± 0.1 0.3 ± 0.0 0.4 ± 0.2 0.5 ± 0.1 
9-HETE 0.2 ± 0.1 8.2 ± 1.5 17.7 ± 1.4 5.0 ± 1.6 9.6 ± 2.4 11.5 ± 1.8 
9-HEPE 9.9 ± 5.0 0.8 ± 0.1 1.3 ± 0.2 8.6 ± 24.5 50.6 ± 14.0 36.2 ± 6.1 
8-HDoHe 11.1 ± 4.9 7.0 ± 1.0 11.5 ± 0.8 10.6 ± 3.8 62.0 ± 13.1 67.5 ± 9.1 
16-HDoHe 5.8 ± 2.4 4.6 ± 0.6 8.6 ± 0.6 6.4 ± 2.1 40.6 ± 8.7 48.6 ± 7.0 
20-HDoHe 12.8 ± 5.3 9.9 ± 1.3 18.4 ± 1.3 14.1 ± 4.8 77.8 ± 16.2 92.3 ± 12.8 
 
 
Table 5.3.  EPA- and DHA-derived MHM are increased in fish oil-fed mice 
(145).  LC-MS/MS-determined eicosanoid levels in joint of mice fed the fish oil or 
soy oil diets on days 0, 10, and 21 post-infection.  Values represent mean ± 
SEM.  (Values determined by Dr. Darren S. Dumlao.  Table created by Anna M 
Cunningham based on a table generated by Dr. Darren S. Dumlao.) 
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 Taken together, this data suggested that Bb infection induced a 
substantial amount of oxidative stress that resulted in non-enzymatic metabolism 
of MHM.  Furthermore, EPA- and DHA-derived MHM were more susceptible to 
non-enzymatic metabolism in this model.  As metabolism of EPA- and DHA-
derived MHM results in the production of putative anti-inflammatory metabolites, 
this data suggests a mechanism whereby dietary fish oil may induce an anti-
inflammatory microenvironment. 
 
D. Dietary fish oil substitution alters COX metabolite production. 
 Cyclooxygenase (COX)-2 metabolites are known to play a large role in the 
immune response to Bb (141, 143) and inflammation in general (232).  
Furthermore, in RAW264.7 macrophages, it has been shown that EPA and DHA 
treatment results in inhibition of both COX-1 and COX-2 (233, 234) and a 
preferential usage of substrate (AA) by the lipoxygenase (LOX) pathway, leading 
to increased production of leukotrienes and other lipoxygenase metabolites 
(235).  Therefore, we wanted to assess the effect of dietary FO substitution on 
this pathway during experimental Lyme disease.   
 6-keto-prostaglandin F2α (6k-PGF2α) is a stable breakdown production of 
the potent, but very bioactive vasodilator, PGI2.  We found that levels of 6k-
PGF2α were increased throughout Bb infection in the joints of SO-fed mice, but 
were reduced by 71% in the joints of mice fed the FO-diet by day 21 post-
infection (fig. 5.5).  TXB2, a stable breakdown product of the vasoconstrictive 
TXA2, was  
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found at low levels throughout the course of disease in joints of SO-fed mice, but 
was found at even lower levels the joints of FO-fed mice.  Surprisingly, the EPA-
derived analogs of these molecules, Δ17,6k-PGF1α and TXB3, were not detected 
in the FO-fed mice.  These data suggested that FO substitution reduced the 
production of AA-derived vaso-regulatory eicosanoids by COX-2, but perhaps by 
mechanisms other than providing alternative substrates such as direct inhibition 
(233, 234). 
 PGE2 (202-204, 208, 236-240) and PGD2 (241) are two classically 
immuno-regulatory, AA-derived, COX-2 metabolites.  As expected (144), in the 
SO-fed mice, these metabolites were increased throughout the course of 
infection (fig. 5.6 A, B).  Although these metabolites were also increased 
throughout the course of infection in FO-fed mice, their production was 
significantly attenuated at day 21 post-infection compared to the SO-fed mice.  
The analogous EPA-derived 3-series prostaglandins (PGE3 and PGD3) were 
found at low levels throughout the course of infection in SO-fed mice, but were 
increased significantly in the FO-fed mice (fig. 5.6 C, D).  These data suggested 
that dietary FO substitution resulted in the preferential use of ω-3 substrates by 
COX-2.  As the 3-series PGs are believed to be less bioactive than their AA-
derived counterparts (216), this could suggest another mechanism by which 
dietary FO promoted an anti-inflammatory microenvironment. 
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Fig. 5.5.  Cyclooxygenase-derived AA metabolites are reduced in fish oil 
diet-fed mice (145).  Amounts of cyclooxygenase (COX)-derived (A) 6-keto-
prostaglandin F1α (6k-PGF1α) and (B) thromboxane B2 (TXB2) in the ankles of soy 
oil (SO)- or fish oil (FO)-fed mice on days 0, 10, and 21 post-infection.  Values 
represent mean ± SEM, n = 4 on days 0 and 10 and 9 on day 21 post-infection.  * 
indicates a significant difference in eicosanoids produced in the FO-fed mice 
compared to the SO-fed mice, p < 0.05.  (Quantification of eicosanoids and 
generation of figure by Dr. Darren S. Dumlao.) 
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Fig. 5.6.  Dietary fish oil substitution results in the preferential use of EPA 
and DHA substrates for metabolism via cyclooxygenase-2 (145).  
Cyclooxygenase (COX)-2-derived PGE2, PGD2, and related metabolites were 
quantified in the joints of Bb-infected mice fed either SO or FO diets using LC-
MS/MS on days 0, 10, and 21 post-infection.  Values are means ± SEM, n = 4 at 
day 0 and 10 post-infection and 9 on day 21 post-infection.  # denotes a 
significant difference in metabolite production from day 0 within a diet and * 
denotes a significant difference in eicosanoid production in the FO-fed mice 
compared to SO-fed mice, p < 0.05.  (Values determined and figure constructed 
by Dr. Darren S. Dumlao.) 
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 Surprisingly, FO-fed mice accumulated high levels of the AA-derived 
PGD2 dehydration product 15-deoxy-PGJ2 (fig. 5.6 E).  In fact, levels of 15d-
PGJ2 in the joints of FO-fed mice accumulated to levels comparable to levels of 
PGE2 in the joints of SO-fed mice (fig. 5.6 B), suggesting that the FO diet was 
shunting AA metabolism from PGE2 synthesis to PGD2 synthesis.  To examine 
this more closely, we calculated the total amount of metabolites detected from 
the PGE2 and PGD2 pathways (“PGE2 total” and “PGD2 total”) in either diet (fig. 5.7).  
We found that, in the SO-fed mice, PGE2-related products were more abundant 
that PGD2-related products at days 10 and 21 post-infection (fig. 5.7 A). In the 
FO-fed mice, the levels of PGE2-related products were decreased in comparison 
to levels seen in the SO-fed mice, and levels of PGD2-related products were 
increased (fig. 5.7 B).  When we looked at the ratio of PGE2-related products to 
PGD2-related products in the SO or FO diet, we found that the ratio of PGE2-
related products to PGD2-related products was significantly decreased at days 10 
and 21 post-infection in the FO-fed mice compared to the SO-fed mice (fig. 5.7 
C).   
 These data suggested that dietary FO had drastic effects on the 
production of mediators through the COX-2 pathway via competitive substrate 
usage, enzyme inhibition, and preferential PG synthesis.  15d-PGJ2 is known to 
have potent anti-inflammatory activities, mainly via signaling through PPARγ and 
inhibition of NF-κB activation (65-68, 241-243).  The fact that dietary FO 
substitution resulted in the production of large quantities of this metabolite 
suggests yet  another mechanism by which ω-3 fatty acids are able to induce  
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Fig. 5.7.  Dietary fish oil substitution results in a redirection of COX-2-
mediated AA metabolism from PGE2 to PGD2 (145).  Total amounts of PGE2-
related products (PGE2 total) and PGD2-related products (PGD2 total) were 
determined in the joints of mice fed the (A) soy oil (SO) diet or (B) the fish oil 
(FO) diet at days 0, 10, and 21 post-infection.  Using these values, the ratio of 
PGE2 total to PGD2 total was determined in the SO and FO diets (C).  Values are 
mean SEM, n = 4 on days 0 and 10 post-infection and 9 on day 21 post-infection.  
* denotes a significant difference between PGE2 total and PGD2 total (A, B) and 
between diets (C), p < 0.05.  (Values were calculated and figure was developed 
by Dr. Darren S. Dumlao.) 
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an anti-inflammatory microenvironment. 
 
E. Dietary fish oil substitution does not affect Lyme arthritis severity, joint 
immune cell composition, or joint Bb loads. 
 Infection Bb results in the development of severe inflammatory arthritis 
that is mediated by neutrophils (134).  Eicosanoids are known to play a 
significant role throughout the course of Lyme arthritis (fig. 5.1) (144).  COX-1 
metabolites are important for germinal center development and specific antibody 
production in response to Bb infection (143) and COX-2 and 5-LOX are known to 
play important roles in the resolution of inflammation in this model (141, 142).  
Due to the drastic effects on the eicosanoid profile and the tendency toward the 
production of molecules that were either less bioactive or anti-inflammatory in 
nature in response to dietary fish oil substitution, we hypothesized that 
inflammation resulting from infection with Bb would be attenuated.  To address 
this, we fed mice either the FO diet or the SO diet for 2 weeks prior to infection 
with 1×105 Bb and monitored the progression of ankle swelling (fig. 5.8 A).  We 
found that mice fed the FO diet developed ankle swelling identical to the mice fed 
the SO diet, indicating that dietary FO substitution does not affect joint swelling in 
this model. 
 Although joint swelling is typically indicative of underlying inflammation 
resulting from Bb infection, some exceptions have been noted (142, 153).  Thus, 
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Fig. 5.8.  Dietary fish oil does not alter the progression of Lyme arthritis 
(145).  Swelling (A) of the soy oil (SO)- and fish oil (FO)-fed mice was assessed 
using metric calipers.  Arthritis severity scores (B), arthritis type scores (B), and 
Borrelia loads (C) shown are from joints on day 21 post-infection.  Values in (A) 
and (B) are means ± SEM.  In (C), each symbol represents an individual mouse 
and bars represent the median value.  n = 10 per group.  Results are 
representative of 3 separate experiments all yielding similar results. 
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to more definitively determine whether dietary FO substitution had an effect on 
Lyme arthritis development, we used H & E-stained joint sections to assess 
arthritis severity of FO- and SO-fed mice at days 10 and 21 post-infection.  We 
calculated severity scores on a scale of 0 – 4, where 0 represents no 
inflammation and 4 represents severe inflammation, as described previously 
(244) and in Materials & Methods.  We found no significant difference in arthritis 
severity in mice fed the FO diet compared to those fed the SO diet (fig. 5.8 B) 
suggesting that dietary FO substitution does not affect inflammation resulting 
from Bb infection. 
 Neutrophils are known to mediate the development of Lyme arthritis and 
are the predominant cell type during severe joint inflammation in this model (130, 
134).  Macrophages tend to predominate later during the infection and correlate 
with resolution of Lyme arthritis (130).  To assess the affect of dietary FO on the 
joint immune cell infiltrate, we determined arthritis type scores based on H & E 
stained joint sections, as described in Materials & Methods.  A type score of 0 
indicates the presence of limited immune cells, a type score of 1 indicates a 
predominance of macrophages, and a type score of 4 indicates a predominance 
of neutrophils.  We found no differences in the joint immune cell infiltrates in mice 
fed the FO diet compared to those fed the SO diet (fig. 5.8 B), suggesting that 
dietary FO substitution does not affect recruitment of neutrophils or macrophages 
to sites of Bb infection. 
 We hypothesized that the drastic effects of FO on the eicosanoid profile 
during Bb infection would result in a defect in the ability of mice to clear Bb 
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infection due to attenuated inflammation.  Therefore, we isolated DNA from the 
joints of SO- and FO-fed mice at days 10 and 21 post-infection and used 
quantitative Real-Time PCR to detect copies of bacterial flagellin (FlaB) 
normalized to 1000 copies of mouse nidogen (nido).  However, just as we saw no 
differences in arthritis severity or joint immune cell composition, the mice fed the 
diet in which FO was the primary FA source displayed no defect in their ability to 
clear Bb infection when compared to mice fed the SO diet (fig. 5.8 C). 
 Together, these data indicate that although dietary FO substitution results 
in a drastically altered eicosanoid microenvironment, it does not affect the ability 
of mice to mount an immune response and clear Bb from infected joints. 
 
F. Dietary fish oil substitution does not affect Lyme carditis severity, heart 
immune cell composition, or cardiac Bb loads. 
 Besides arthritis, carditis is also a significant sequelae to infection with Bb.  
To investigate the effect of dietary FO substitution on Lyme carditis, we fed mice 
the FO or SO diets for 2 weeks prior to infection with 1×105 Bb.  On days 10 and 
21 post-infection, we sagittally bisected hearts and used H & E stained tissue 
sections to assess carditis severity and type scores as described in Materials & 
Methods.  We found no difference in the recruitment of immune cells to the 
cardiac tissue of FO-fed mice or the ability of these mice to develop carditis when 
compared to SO-fed mice (fig. 5.9 A).  We also detected no defect in the ability 
of these mice to clear Bb from infected cardiac tissue (fig. 5.9 B). These data 
indicated that, similar to our findings in joint tissue, dietary FO  
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Fig. 5.9.  Dietary fish oil substitution does not alter progression of Lyme 
carditis (145).  Carditis severity and type scores (A) of mice fed a soy oil (SO) or 
fish oil (FO) diet on day 21 post-infection.  Values are mean ± SEM.  (B) Borrelia 
burgdorferi DNA detected in heart tissue of SO- or FO-fed mice on day 21 post-
infection.  Each symbol represents an individual mouse and bars indicate median 
values.  n = 10 per group and data is representative of three separate experiment 
with similar results. 
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substitution does not diminish the ability of mice to mount an immune response 
and clear Bb from infected cardiac tissue. 
 
III. DISCUSSION 
 Lyme disease is the most common vector-borne disease in the United 
States and is endemic in Europe and Asia (120).  It is caused by infection with 
the spirochete Borrelia burgdorferi (Bb) (245).  Lyme disease is treatable with 
antibiotics such as doxycycline, although the treatment window is narrow and 
must take place early on during infection.  As symptoms are ambiguous (flu-like) 
and frequently overlooked, infection often goes undiagnosed.  If left untreated, 
disease progresses to a severe arthritis that localizes to the large joints including 
the knee (222).  Cardiovascular and possibly neurological disorders may also 
arise.   
 Dietary fish oil (FO) consumption has been shown to be beneficial for the 
alleviation of symptoms arising from cardiovascular disease, diabetes, cystic 
fibrosis, rheumatoid arthritis, and cancer (81, 210-214).  However, the exact 
mechanisms by which FO mediates its anti-inflammatory actions are unclear.  
Previous work suggests that the major ω-3 fatty acids (FA) present in FO are 
able to efficiently out-compete ω-6 FA, such as arachidonic acid (AA), for 
incorporation into membrane phospholipids, making them the preferential 
substrate for metabolism via cyclooxygenase (COX) and lipoxygenase (LOX) 
enzymes (215-217).  As the metabolism of FO-derived ω-3 FA [eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA)] results in the production of less 
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bioactive eicosanoids [the 3-series prostaglandins (PG) and 5-series leukotrienes 
(LT)], it would follow that the resulting eicosanoid microenvironment would have 
diminished inflammatory potential.  Furthermore, FO-derived DHA is known to 
directly inhibit the enzyme COX-2 (233, 234), which is responsible for the 
production of prostaglandins that are typically believed to have pro-inflammatory 
functions, such as PGE2.  Recent data has even suggested that FO-derived ω-3 
FA are able to directly influence inflammation via targeted inhibition of important 
immune signaling pathways.  DHA suppresses inducible nitric oxide synthase 
(iNOS) expression and nitric oxide (NO) synthesis in murine peritoneal 
macrophages and RAW264 cells via inhibition of NF-κB activation and 
upregulation of intracellular glutathione (GSH) (220).  EPA and DHA are able to 
prevent inflammasome-driven inflammation via inhibition of NLRP3 and 
subsequent caspase-1 activation and IL-1β secretion (221).  Taken together, 
these studies suggest that dietary FO is able to dampen inflammation through a 
variety of direct and indirect mechanisms. 
 The murine model of experimental Lyme disease recapitulates very well 
the progression of human Lyme disease and allows the study of both arthritis and 
carditis symptoms.  To investigate the effects of dietary FO on Lyme arthritis and 
carditis, we fed mice a diet in which the main FA source was from Menhaden fish 
oil, as opposed to soy oil in the control diet.  The main FAs in FO are EPA and 
DHA, while the main FAs in SO are AA and linoleic acid (LA).  Mice were fed 
these diets for two weeks prior to being infected with Bb, as well as throughout 
the entire course of infection.  Disease was monitored throughout the course of 
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21 days and mice were sacrificed on days 10 and 21 post-infection in order to 
collect tissue samples for assessment of disease severity, immune cell 
composition, and eicosanoid production at these time points.  The hypothesis of 
this study was that mice fed the FO diet would have an altered eicosanoid profile 
that was more anti-inflammatory in nature compared to the mice fed the SO diet, 
leading to attenuated Lyme arthritis and carditis.  Furthermore, we hypothesized 
that the reduced capacity of these mice to produce robust inflammation would 
lead to a defect in their ability to effectively clear infection from these tissues. 
 Indeed, dietary FO substitution resulted in a dramatic alteration of the 
eicosanoid profile.  Whereas the SO-fed mice produced mainly AA- and LA-
derived eicosanoids, their production was dramatically reduced in the mice fed 
the FO diet.  EPA- and DHA-derived eicosanoids, however, were abundant in the 
FO-fed mice.  In fact, dietary FO substitution resulted in compositional changes 
to the eicosanoid profile in every eicosanoid subclass (fig. 5.2).  Although the 
majority of changes to the eicosanoid profile resulting from dietary FO 
substitution were compositional in that the eicosanoids being produced were 
from EPA or DHA origin (as opposed to AA or LA origin), the production of AA-
derived metabolites was also altered.  In SO-fed mice, PGE2 was the most 
abundant COX-2 eicosanoid produced.  However, in FO-fed mice, production of 
PGE2 was drastically reduced and the production of the PGD2 dehydration 
product 15d-PGJ2 was increased.  Interestingly, the levels to which 15d-PGJ2 
was produced in the FO-fed mice was comparable to the levels at which PGE2 
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was produced in the SO-fed mice, suggesting that dietary FO led to a 
“redirection” of AA metabolism from PGE2 synthesis to PGD2 synthesis. 
 The fact that the majority of eicosanoids produced in the FO-fed mice 
were derived from EPA and DHA and thus less bioactive and that even the few 
abundant AA-derived eicosanoids produced were anti-inflammatory in nature 
suggested that the overall tone of the eicosanoid microenvironment in the FO-fed 
mice was anti-inflammatory.  However, when we assessed Lyme arthritis and 
carditis, we found that inflammation in the FO-fed mice was comparable in 
severity and type to that of SO-fed mice.  Furthermore, the ability of FO-fed mice 
to clear Bb from both ankle and heart tissues was equivalent to the SO-fed mice.  
These data suggest that although the eicosanoid profile in the FO-fed mice was 
dramatically altered compositionally, it did not affect the ability of these mice to 
mount an effective immune response and clear infection with Bb. 
 It is important to note that the levels of EPA and DHA provided in our 
experimental diet were 10- to 20-fold what is possible in humans.  Furthermore, 
the rates and abilities of different FA to be incorporated into mouse and human 
membranes can differ dramatically (246) and may also depend on source [e.g.: 
krill oil vs. fish oil (247)].  Thus, the fact that dietary FO substitution resulted in 
such a dramatic shift in the composition of the eicosanoid profile of mice infected 
with Bb likely does not accurately portray what would occur in humans ingesting 
reasonable amounts of dietary FO for the purpose of dampening inflammation.  
While ω-3 FA-derived eicosanoids are less bioactive than their ω-6 counterparts, 
it could be that the excessive amount of ω-3 FA provided in our FO diet allowed 
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the production of such high levels of FO-derived eicosanoids that an 
“inflammatory threshold” was reached allowing Bb-induced arthritis and carditis 
to take place.  For example, although AA-derived LTB4 is a much more potent 
neutrophil chemoattractant and has a higher association constant for binding with 
high-affinity receptors than EPA-derived LTB5, LTB4 and LTB5 are equally potent 
at inducing neutrophil degranulation and binding low-affinity receptors (217).  
Even though AA-derived eicosanoids are much more potent than EPA- or DHA-
derived eicosanoids, it is possible that in the FO-fed mice, EPA- and DHA-
derived eicosanoids reached levels sufficient to induce an immune response.  
The fact that we saw no differences in the severity of inflammation or recruitment 
of immune cells to the sights of infection supports this hypothesis. 
 Another possible explanation for the fact that dietary FO substitution did 
not dampen inflammation resulting from infection with Bb is the fact that 
experimental Lyme disease is not regulated by the NLRP3 inflammasome or 
iNOS, two immune mechanisms inhibited by FO-derived FA.  While Lyme 
arthritis is dependent on caspase-1 cleavage and IL-1β production, this process 
is independent of NLRP3 and is instead mediated by the TLR-2/MyD88 axis 
(248).  While iNOS mRNA expression is up-regulated in response to infection 
with Bb in dogs (249), iNOS-deficient mice have no defect in their ability to 
develop disease, indicating that iNOS is dispensable for the development of 
Lyme arthritis (250).  Interestingly, in a mouse model of colitis it was found that 
dietary FO supplementation led to an increase in the production of the 
chemokine KC (251) which is responsible for the development of Lyme arthritis 
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and carditis (134).  Therefore, it is possible that total KC production was able to 
reach levels enabling the recruitment of neutrophils to sites of infection and 
subsequent development of disease despite an overall anti-inflammatory 
eicosanoid microenvironment in the FO-fed mice. 
 This study demonstrates the complexities that exist in understanding the 
role of eicosanoids in inflammation.  While FO-derived eicosanoids are less 
bioactive than their ω-6 FA-derived counterparts, it is likely that a threshold exists 
after which these eicosanoids can, too, become pro-inflammatory.   Similar to 
many nutritional supplements, it is likely that the effects of FO are only beneficial 
when taken in moderation.  Furthermore, although FO supplementation has been 
shown to be beneficial for the alleviation of rheumatoid arthritis, the fact that we 
saw no difference in Lyme arthritis between FO- and SO-fed mice exemplifies the 
differences that exist in types of inflammation and variables that determine 
capable therapeutic intervention even within different types of arthritis. 
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CHAPTER SIX 
 
DYNAMIC EICOSANOID PRODUCTION DURING AUTOANTIBODY-DRIVEN 
K/BxN SERUM-TRANSFER ARTHRITIS 
 
I. INTRODUCTION 
 The K/BxN model of arthritis was described in 1996 by Kouskoff, et al. 
(252) and is the prototypical model for arthritides that are regulated by 
autoantibodies and immune complexes.  It is widely used in an effort to delineate 
mechanisms that may regulate human Rheumatoid arthritis (RA) due to the many 
similarities that exist between the two arthritides including synoviocyte 
proliferation, synovitis, leukocyte invasion, pannus formation, erosion of cartilage 
and bone, polyclonal B cell activation, hypergammaglobulinemia, and 
autoantibody production (252, 253). 
 K/BxN mice are generated when mice transgenic for the KRN T cell 
receptor (TCR), which recognizes the bovine ribonuclease peptide RNase 42-56 
presented by I-Ak MHC II, are crossed with NOD mice.  Inflammation develops 
due to the KRN TCR aberrantly recognizing a peptide derived from the 
ubiquitously expressed glucose-6-phosphate isomerase (GPI) presented by NOD 
Ag7 MHC II.  K/BxN mice develop severe, chronic polyarthritis around 4-5 weeks 
of age.  Arthritis in K/BxN mice is fully dependent on the transgenic KRN TCR 
and the breaking of tolerance leading to production of autoantibodies recognizing 
GPI (253, 254).  GPI autoantibody effector function in K/BxN mice is regulated by 
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the alternative pathway of complement, most notably C5a (255-257).  The 
localization of inflammation to joint tissue despite recognition of a ubiquitously 
expressed peptide is believed to be due to the lack of cell membrane-bound 
complement inactivators such as decay-accelerating factor (DAF/CD55) and 
membrane cofactor of proteolysis (MCP/CD46) expressed on cartilage.  
Localization of inflammation to the joint may further be explained by the formation 
of complement factor 3 (C3)-IgG (anti-GPI) immune complexes (IC) that develop 
on the cartilage surface, resulting in the activation of the alternative complement 
pathway and subsequent cleavage of C5a from C5 (255). 
 The transfer of serum containing anti-GPI autoantibodies from K/BxN mice 
to wild-type recipient mice leads to the development of a transient arthritis, in 
which severity and duration correlates with the presence and eventual 
degradation of anti-GPI autoantibodies present in the passaged serum.  This 
model allows for the study of effector mechanisms that regulate arthritis 
independent of the breaking of tolerance in K/BxN mice.  Inflammation resulting 
from the transfer of K/BxN serum is independent of adaptive immunity and is 
dependent on innate immune cells, most notably PMN, which are indispensible 
for the development of disease (163, 164, 258). 
 Eicosanoids, a major component of the innate immune compartment, have 
been shown to play regulatory roles in the development of K/BxN serum-transfer 
arthritis (KSTA).  Cyclooxygenase-1 (COX-1)-derived prostacyclin (PGI2) 
signaling through its cognate receptor, IP, is required for both the development 
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and maintenance of arthritis in this model, while COX-2-derived prostaglandins 
appear dispensable (259).   
 5-lipoxygenase (5-LOX)-derived leukotriene B4 (LTB4) plays numerous 
roles in the development of KSTA.  In order for LTB4 to be produced, 5-LOX must 
translocate to the nuclear envelope and associate with 5-LOX activating protein 
(FLAP).  This complex metabolizes arachidonic acid (AA) into leukotriene A4 
(LTA4), which is metabolized into LTB4 by LTA4 hydrolase (LTA4H).  
Approximately 20% of in vivo LTB4 production results from transcellular 
biosynthesis, in which LTA4 is secreted by 5-LOX-expressing cells (bone marrow-
derived myeloid cells) and metabolized by neighboring LTA4H-expressing cells 
(260).  In 2010, Chen et al. observed that transcellular biosynthesis of LTB4 plays 
a significant role in the development and maintenance of KSTA (110).  It was 
found that radio-resistant (bone marrow-derived) cells, most likely PMN, produce 
LTA4, which is metabolized by LTA4H-expressing fibroblast-like synoviocytes 
(FLS) into LTB4.  In this study, LTB4, acting through its cognate receptor BLT-1, 
stimulated FLS invasion and migration, as well as FLS-mediated erosive pannus 
formation (110).   
 Further studies have implicated LTB4 as part of a “lipid-cytokine-
chemokine cascade” that mediates multiple “waves” of PMN recruitment and 
subsequent development of KSTA (261).  These studies suggest that following 
passage of K/BxN serum, C5a signals through C5aR on a “first wave” of PMN 
and induces the production of LTB4 by these cells.  LTB4 produced by the “first 
wave” of PMN signals through BLT-1 to recruit a “second wave” of PMN, which 
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are activated by immune complex (IC) signaling through the FcγRIII, leading to 
the production of IL-1β.  This “second wave” of PMN participate in their own 
recruitment both directly, by expressing the chemokines CXCL2 and CCL3, and 
indirectly via production of IL-1β, which induces the production of CXCL1, 
CXCL5, CCL4, and CCL9 by joint structural cells (261, 262).  This rapid and 
massive accumulation of cytokine- and LTB4-producing PMN at the cartilage 
surface results in a destructive arthritis due to the stimulation of local pro-
inflammatory cytokine production and FLS invasion, migration, and erosive 
pannus formation (110).  While the majority of studies suggest that the 
LTB4/BLT-1 axis is the main signaling pathway by which LTB4 mediates its 
activity, in a study using LTB4R knock-out mice (BLT-1-/- and BLT-2-/-), it was 
found that BLT-1 and BLT-2 both play significant, yet non-redundant roles in the 
development of KTSA (263). 
 We have previously completed a study in which we assessed the temporal 
production of 104 distinct eicosanoid species throughout the course of Lyme 
arthritis (144).  In the present study, we utilized the same protocol in order to 
determine the production of eicosanoids throughout the course of KSTA.  The 
mechanisms by which eicosanoids regulate inflammation in these two models 
are dissimilar; While COX-1-derived metabolites regulate the development and 
maintenance of KSTA, COX-2-derived metabolites seem to play a greater role in 
Lyme arthritis (141).  5-LOX metabolites play a role in the regulation of 
inflammation in both models, albeit to a lesser extent in Lyme arthritis (142).  The 
results herein serve to demonstrate that although inflammatory arthritides may 
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have overlapping disease manifestations and perhaps even similar pathways that 
converge downstream, the mechanisms that regulate inflammation vary 
drastically and depend on the original instigating source of inflammation.  It is 
crucial to keep this information in the forefront of the mind when efforts are being 
made to translate research preformed in murine model systems to the 
development of therapeutics for human disease. 
 
II. RESULTS 
A. Passage of K/BxN serum to C3H/HeJ mice results in severe polyarthritis. 
 In order to induce arthritis, we injected 4-6 week old C3H/HeJ mice with 
pooled serum isolated from arthritic K/BxN mice and boosted them two days 
later, as described (264).  We monitored disease throughout the course of 
arthritis by determining clinical scores based on front on hind paw edema, as 
described in Monach, et al. 2008 (264), and by measuring dorsovental swelling of 
hind joints using metric calipers (fig. 6.1 A, B).  Injection of K/BxN serum resulted 
in progressive paw swelling, involving both front and hind paws, that peaked at 
day 10 post-serum transfer.  On days 3, 7, 14, 17, and 21 post-serum transfer, 
we collected joint tissue from arthritic mice and compared histologically-
determined arthritis severity and type scores to control mice that had been 
injected with normal mouse serum (NMS) (fig. 6.1 C, D).  Arthritis severity 
correlated with levels of paw edema and suggested that the peak of arthritis 
occurred between days 7 and 14 post-serum transfer.  Arthritis type scores are 
generated in an effort to determine cell types present in joint tissue.   
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Fig. 6.1. Severe arthritis develops in response to passage of K/BxN serum 
to C3H/HeJ mice.  K/BxN or normal mouse serum was injected intraperitoneally 
(i.p.) into C3H/HeJ mice and disease was allowed to progress for 21 days.  
Clinical scores (A) were determined as described by Monach, et al. 2008 (264), 
and represent the sum of paw scores rated on a 1-4 scale.  Swelling (B) was 
determined using metric calipers and by subtracting day 0 values from 
subsequent measurements.  Jennifer Hughes-Hanks generated Severity (C) and 
type (D) scores by histological assessment of H & E-stained joint sections.  
Values represent mean ± SD. 
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Lower type scores indicate a predominance of macrophages in joint tissue, while 
higher type scores indicate a predominance of neutrophils.  We found that the 
highest type scores were observed on days 3 through 17 post-serum transfer, 
suggesting neutrophils were the dominant cell type in arthritic lesions at these 
time points.  The dominance of neutrophils during the peak of K/BxN serum 
transfer arthritis (KSTA) corroborates data implicating neutrophils as mediators of 
inflammation in this model (163, 164, 258). 
 
B. Eicosanoid enzymatic pathways are activated during KSTA. 
 On days 3, 7, 14, 17, and 21 post-serum transfer, we extracted lipids from 
joint tissue and quantified eicosanoids using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) as previously described (144).  This allowed us to 
determine the production of eicosanoids throughout the course of KSTA.  Using 
this information, we generated a heat map displaying the relative fold change of 
eicosanoids compared to production in control, NMS-treated mice (fig. 6.2).  This 
data indicated that, throughout the course of KSTA, arachidonic acid metabolites 
were dynamically affected.   
 To better understand the enzymatic pathways that were being activated in 
response to the passage of K/BxN serum, we assessed enzyme usage based on 
the fold change data displayed on the heat map.  We determined the percent of 
metabolites that were affected, positively or negatively, in each pathway in 
response to transfer of K/BxN serum.  This allowed us to assess both total 
enzyme usage (fig. 6.3 A) and temporal enzyme usage (fig. 6.3 B), suggesting 
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Fig. 6.2.  Joint eicosanoids are dynamically affected by passage of K/BxN 
serum.  Heat map displays the relative fold change of select AA-derived 
eicosanoids in the joints of mice on days 3, 7, 14, 17, and 21 post-K/BxN serum 
transfer compared to expression in the joints of mice passaged with normal 
mouse serum (NMS, “day 0”).  For eicosanoids that were ND on day 0, the 
relative fold change was determined from the day that they first were detected.  
ND (black) indicates that an eicosanoid was either not detected or was detected 
in concentrations below the limit of detection.  n = 5 on day 0, 9 on day 3 and 14, 
10 on day 7 and 21, and 8 on day 17 post-serum transfer.  (LC-MS/MS analysis 
and composition of heat map by Dr. Darren S. Dumlao.) 
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Fig. 6.3. Eicosanoid enzymatic pathways engaged during KSTA.  Enzymatic 
pathway usage was determined by calculating the percentage of metabolites that 
were affected by a fold change of 1 or more in a given pathway at any given time 
(A).  Temporal enzyme usage was determined by calculating the percentage of 
metabolites affected by a fold change of 1 or more in a given pathway on days 3, 
7, 14, 17, and 21 post-serum transfer (B).  (LC-MS/MS analysis performed by Dr. 
Darren S. Dumlao, calculation of enzyme usage performed by Anna M. 
Cunningham.) 
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 which pathways were affected during KSTA.  The majority of metabolites that 
were affected were generated either non-enzymatically or via the cytochrome 
P450 (CYP) pathway, suggesting that metabolites produced through these 
pathways are important mediators of KSTA. 
 
C. Dynamic regulation of Cytochrome P450 metabolites during KSTA. 
 The CYP pathway is responsible for the production of two major groups of 
vasoactive eicosanoids, the hydroxyeicosatetraenoic acids (HETEs) and the 
epoxyeicosatetraenoic acids (EETs).  For the most part, the HETEs (e.g.: 20-
HETE) are vasoconstrictive and the EETs (e.g.: 11,12-EET) are vasodilatory 
(265).  In general, these activities are mediated via regulation of calcium-
dependent potassium channels (266-268).  The CYP pathway has been 
implicated to correlate in some instances with arthritis, as hepatic levels of CYP 
subfamily enzymes were elevated in a rat model of adjuvant-induced arthritis 
(269) and a study of Taiwanese Rheumatoid arthritis patients noted that a 
polymorphism in the human gene CYPIAI correlated with resistance to disease 
(270-273). 
 We observed that the CYP pathway was dynamically affected during 
KSTA (fig. 6.3 A, B) and thus examined more closely the production of the CYP 
metabolites 16-HETE, 18-HETE, 19-HETE, and 20-HETE (fig. 6.4 A-D).  While 
CYP metabolites are, for the most part, accepted to be vasoconstrictive, 16-
HETE, 18-HETE, and 19-HETE have been observed to have vasodilatory 
functions (265).  These discrepancies may be explained by the fact that the  
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Fig. 6.4. Cytochrome P450-derived hydroxyeicosatetraenoic acids (HETEs) 
expression in joints of arthritic mice.  Cytochrome P450 (CYP)-derived 
HETEs were quantified in the joints of mice that had received either K/BxN or 
normal mouse serum using LC-MS/MS on days 0, 3, 7, 14, 17, and 21 post-
transfer.  Values are means ± SD, n = 5 on day 0, 9 on day 3 and 14, 10 on day 
7 and 21, and 8 on day 17 post-serum transfer.  (Values by Dr. Darren S. 
Dumlao, figures by Anna M. Cunningham.) 
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function of these molecules appears to be tissue-specific and may vary 
depending on the vascular bed (274).  20-HETE, however, has been shown in 
numerous studies to be a reliable and potent vasoconstrictive metabolite (266).  
In fact, increased 20-HETE expression resulting from inhibition of 
cyclooxygenase-2 (COX-2) has been found to be responsible for the increased 
risk of heart attack associated with the drug Vioxx® (rofecoxib) (275).  The 
expression of 16-HETE, 18-HETE, 19-HETE, and 20-HETE peaked 
concomitantly at day 7 post-serum transfer (fig. 6.4 A-D), likely playing a role in 
regulating the influx of immune cells to the site of inflammation. 
 CYP-derived EETs are potent vasodilators, but have also been shown to 
play a role in mitogenesis and the production of hormones such as growth factors 
and vasopressin (276-278). These molecules are also anti-inflammatory as they 
inhibit the expression of adhesion molecules on endothelial cells (279).  We 
found that, similar to the CYP-derived HETEs, the expression of 5,6-EET, 8,9-
EET, 11,12-EET, and 14,15-EET peaked on day 7 post-serum transfer (fig. 6.5 
A-D).  As these molecules are potent vasodilators and mitogens, it is likely that at 
these time points they are upregulated to allow for tissue infiltration of immune 
cells and to induce synoviocyte proliferation.  Although their expression appears 
to wane slightly at later time points, the expression of these metabolites remains 
higher than the HETEs throughout the course of KSTA (fig. 6.5).  This suggests 
that the balance of vasodilatory and vasoconstrictive metabolites is tipped toward 
the former, allowing vascular permeability for the influx of immune cells.  
Furthermore, as these metabolites have anti-inflammatory activity, their  
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Fig. 6.5. Cytochrome P450-derived epoxyeicosatetraenoic acids (EETs) are 
produced in the joints of arthritic mice.  Cytochrome P450 (CYP)-derived 
EETs were quantified in the joints of mice that had received either K/BxN or 
normal mouse serum using LC-MS/MS on days 0, 3, 7, 14, 17, and 21 post-
transfer.  Values are means ± SD, n = 5 on day 0, 9 on day 3 and 14, 10 on day 
7 and 21, and 8 on day 17 post-serum transfer.  (Values by Dr. Darren S. 
Dumlao, figures by Anna M. Cunningham.) 
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expression at later time points could serve to limit inflammation and induce 
resolution. 
 
D. Expression of non-enzymatically generated eicosanoids during KSTA. 
 Non-enzymatic metabolite production is a reliable indicator of a 
microenvironment with high oxidative stress (280).  Two notable metabolites 
produced via non-enzymatic mechanisms, 5-iso PGF2α IV and 8-iso PGF2α III, 
are elevated in Rheumatic diseases (281) and in certain instances may exert 
vasoconstrictive activity (282).  We measured the production of these metabolites 
and found that although 5-iso PGF2α IV remained unchanged throughout the 
course of KSTA, 8-iso PGF2α III was upregulated in response to the transfer of 
arthritic K/BxN serum, peaked at day 7 post-serum transfer, and remained 
elevated throughout the course of disease (fig. 6.6 A, B).  As this molecule has 
vasoconstrictive activity, its upregulation at day 7 and continued elevation 
throughout the remainder of disease could suggest that it acts as a counter-
regulator to the highly expressed vasodilatory EETs, functioning to limit further 
vascular leakage and immune cell infiltration and induce the resolution of 
inflammation. 
 As the non-enzymatic pathway of metabolite generation is highly activated 
in KSTA (fig. 6.3), we assessed the production of other non-enzymatically 
produced metabolites including 9-HETE, 8-HDoHE, 16-HDoHe, and 20-HDoHe 
(fig. 6.6 C-F).  The expression of these metabolites was elevated throughout the 
course of disease, but peaked at day 7 post-serum transfer.  The fact that these  
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Fig. 6.6. Non-enzymatic eicosanoid production in joints of arthritic mice.  
Non-enzymatically produced eicosanoids were quantified in the joints of mice 
that had received either K/BxN or normal mouse serum using LC-MS/MS on 
days 0, 3, 7, 14, 17, and 21 post-transfer.  Values are means ± SD, n = 5 on day 
0, 9 on day 3 and 14, 10 on day 7 and 21, and 8 on day 17 post-serum transfer.  
(Values by Dr. Darren S. Dumlao, figures by Anna M. Cunningham.) 
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enzymes were produced to such high levels throughout the course of disease 
indicates that the microenvironment generated in response to the transfer of 
arthritic K/BxN serum is highly oxidative.  This data is in agreement with a study 
demonstrating that oxidative stress mediates the severity of arthritis in this 
model, as mice lacking heme oxygenase-1 (HO-1), a potent anti-oxidative stress 
defense molecule, develop exaggerated arthritis severity (283).  
 
E. Cyclooxygenase metabolite production during KSTA. 
 Cyclooxygenase (COX) enzymes (COX-1 and COX-2) are known to have 
a variety of homeostatic and immune-modulating functions (60, 83, 140, 141, 
143, 284-287).  COX-1 is expressed constituitively in most tissues, while COX-2 
is upregulated in response to stimuli such as inflammation.  This pattern of 
expression has led to the hypothesis that COX-1 functions as a housekeeping 
enzyme while COX-2 and its metabolites are mainly involved in inflammation.  
However, this is not always the case as COX-1 is known to have functions in 
immunity (143, 259) and COX-2 is involved in gut and kidney homeostatic 
maintenance (288, 289).  In the K/BxN serum transfer model, COX-1 and its 
metabolite PGI2 are important for the development and maintenance of arthritis 
while COX-2 and its metabolite PGE2 are dispensable (259).   
 We measured the production of COX-1- and COX-2-derived eicosanoids 
throughout the course of KSTA (fig. 6.7).  We found that endogenous (NMS-
treated) levels of 6-keto-PGF1α (6k-PGF1α), the stable breakdown product of 
PGI2, were elevated but decreased upon transfer of arthritic K/BxN serum.   
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Fig. 6.7. Cyclooxygenase (COX)-derived metabolite production in the joints 
of arthritic mice.  Cyclooxygenase (COX)-derived metabolites were quantified in 
the joints of mice that had received either K/BxN or normal mouse serum using 
LC-MS/MS on days 0, 3, 7, 14, 17, and 21 post-transfer.  Values are means ± 
SD, n = 5 on day 0, 9 on day 3 and 14, 10 on day 7 and 21, and 8 on day 17 
post-serum transfer.  (Values by Dr. Darren S. Dumlao, figures constructed by 
Anna M. Cunningham.) 
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However, levels of this metabolite elevated to endogenous levels on day 7 post 
serum-transfer, decreased again on days 14 and 17, and became elevated once 
again on day 21 (fig 6.7 A).  PGI2 is a potent vasodilator that is found at high 
levels in the synovial fluid of Rheumatoid arthritis patients (193).  In a model of 
collagen-induced arthritis (CIA), the production of PGI2 is induced when IL-1β 
stimulates the production of IL-6 by synovial fibroblasts (290).  As IL-1β is 
believed to mediate a “second wave” of PMN in KSTA (261, 291), it is likely that 
the detection of PGF2α at these time points is representative of the PGI2 that was 
produced by this “second wave” of PMN or even a “third wave” of PMN that the 
“second wave” recruited.  Thromboxane B2 (TXB2) is the stable breakdown 
product of the COX-1 metabolite TXA2.  TXB2 was found at extremely high levels 
in NMS-treated control mice as well as throughout the course of arthritis in K/BxN 
serum-treated mice (fig. 6.7 B).  As TXA2 is a potent vasoconstrictor, it is 
possible that this molecule was being expressed at such high levels in order to 
counter the production of the many vasodilatory EETs.  
 12-hydroxyheptadecatrienoic acid (12-HHT) is a COX-1 derived 
eicosanoid that is a high affinity ligand for the LTB4 receptor, BLT-2 (292).  We 
found that 12-HHT was increased throughout the course of KSTA, peaking on 
day 7 post-serum transfer, remaining elevated at day 14, and gradually 
decreasing to endogenous low levels of expression (fig. 6.7 C).  In vitro, 12-HHT 
signaling through BLT-2 induces PMN chemotaxis and, in vivo, the presence of 
BLT-2 on bone marrow cells is required for full development of KSTA (263).  
Although LTB4 signaling through BLT-1 was shown to be responsible for PMN 
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recruitment in vitro, it is likely that 12-HHT can function in a redundant fashion in 
vivo if necessary.  High levels of arachidonic acid (AA) (≥10 µM) are able to 
inhibit the production of LTB4 by human peripheral blood neutrophils (PBN) by 
preventing the dimerization of 5-LOX activating protein (FLAP) (293).  AA can 
accumulate to high levels when cells are in inflammatory conditions, thus it is a 
distinct possibility that during the peak of arthritis, LTB4 production is abrogated 
and the redundant function of 12-HHT allows signaling through BLT-2 to 
progress. 
 Although not absolutely required for the development of KSTA, COX-2-
derived prostaglandins are highly immuno-regulatory and likely play at least a 
minor role in the modulation of arthritis severity in this model.  We found that 
PGE2 and PGF2α were increased to a peak of expression at day 7 post-serum 
transfer (fig. 6.7 D, E).  Whether PGE2 functions as a pro- or anti-inflammatory 
mediator in inflammatory arthritis is variable.  It has been suggested that 
although PGE2 may play an inflammatory role, its production is necessary to 
induce a “switch” from inflammation to resolution (82).  In a model of CIA, 
inhibition of PGE2 production resulted in suppression of arthritis (294).  However, 
in a model of collagen antibody-induced arthritis, which is independent of 
adaptive immunity, inhibition of PGE2 production resulted in exacerbated arthritis 
(295).  This data may suggest that PGE2 may play an anti-inflammatory role in 
models of inflammatory arthritis that do not involve adaptive immunity.  
Therefore, it could be postulated that PGE2 acts as an anti-inflammatory 
mediator in KSTA and its peak of expression at day 7 post-serum transfer could 
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represent an effort to induce mechanisms of resolution (fig. 6.7 D).  Inflammation 
resulting from transfer of K/BxN serum to COX-2-/- mice is indistinguishable from 
inflammation in WT mice; however, as the resolution of KSTA is mediated by the 
degradation of anti-GPI antibodies, it is likely that even if resolution mechanisms 
were not intact, arthritis would subside.  Thus, the role of COX-2/PGE2 in KSTA 
remains somewhat unclear. 
  
F. Lipoxygenase production during KSTA. 
 5-lipoxygenase-derived metabolites are produced at greater quantities by 
stimulated mononuclear cells isolated from patients with Rheumatoid arthritis 
when compared to stimulated mononuclear cells isolated from healthy controls 
(296).  5-LOX-/- mice are resistant to the development of KSTA as LTB4 signaling 
through its receptor, BLT-2, is required for the development of arthritis in this 
model (109, 263).  We found that the production of LTB4 was elevated in the 
joints of mice throughout the course of KSTA (fig. 6.8 A) corroborating its role as 
a regulator of inflammation in this model.  Another metabolite of the 5-LOX 
pathway, 5-HETE, can induce the migration of neutrophils through epithelial and 
endothelial barriers (297).  We found that 5-HETE expression was modestly 
increased at day 7 post-serum transfer (fig. 8 B), which may suggest a possible 
role in the recruitment of neutrophils to sites of inflammation. 
 12/15-lipoxygenase-deficient (12/15-LOX-/-) mice develop exacerbated 
arthritis resulting from passage of K/BxN serum suggesting that metabolites 
generated through this pathway function to limit inflammation (298).  Inhibition of  
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Fig. 6.8. 5-lipoxygenase (5-LOX)-derived metabolite production in the joints 
of arthritic mice.  5-lipoxygenase (5-LOX)-derived eicosanoids were quantified 
in the joints of mice that had received either K/BxN or normal mouse serum using 
LC-MS/MS on days 0, 3, 7, 14, 17, and 21 post-transfer.  Values are means ± 
SD, n = 5 on day 0, 9 on day 3 and 14, 10 on day 7 and 21, and 8 on day 17 
post-serum transfer.  (Values by Dr. Darren S. Dumlao, figures constructed by 
Anna M. Cunningham.) 
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12/15-LOX correlated with increased activation of p38 MAP kinase, increased 
production of IL-6, IL-1β, IFNγ, and KC, and decreased production of the anti-
inflammatory lipoxin A4 (LXA4) (298). We measured the production of 12-HETE, 
15-HETE, HXA3, LXA4, and PD1, all products of this enzymatic pathway and all 
of which are implicated to have anti-inflammatory functions (fig. 6.9).  We found 
that while the production of 12-HETE (fig. 6.9 A) and PD1 (fig. 6.9 E) remained 
relatively unchanged throughout the course of KSTA, 15-HETE (fig. 6.9 B), HXA3 
(fig. 6.9 C), and LXA4 (fig. 6.9 D) appeared to increase and peak at day 7 post-
serum transfer.  The peak of these anti-inflammatory metabolites at day 7 post-
serum transfer may corroborate with data suggesting that anti-inflammatory 
metabolites must be produced early during disease in order for functional 
resolution to take place at later time points (7, 299).  12-HETE, HXA3, and 15-
HETE were expressed in large quantities, while LXA4 and PD1 accumulated to 
only small amounts.  However, the quantities to which these metabolites are 
produced may or may not correlate with their activity, as many of these 
molecules are extremely potent and can have important functions even when 
produced in small quantities. 
 
G. KSTA has a higher pro-inflammatory index than Lyme arthritis. 
 We calculated inflammatory indices based on the production of pro- and 
anti-inflammatory eicosanoids throughout the course of KSTA, as described in 
the supplemental methods of Tam, et al. 2013 (300) (fig. 6.10 A).  Our data  
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Fig. 6.9.  12/15-lipoxygenase (12/15-LOX)-derived metabolite production in 
the joints of arthritic mice.  12/15-lipoxygenase (12/15-LOX)-derived 
metabolites were quantified in the joints of mice that had received either K/BxN 
or normal mouse serum using LC-MS/MS on days 0, 3, 7, 14, 17, and 21 post-
transfer.  Values are means ± SD, n = 5 on day 0, 9 on day 3 and 14, 10 on day 
7 and 21, and 8 on day 17 post-serum transfer.  (Values by Dr. Darren S. 
Dumlao, figures constructed by Anna M. Cunningham.) 
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Fig. 6.10.  Inflammatory indices of mice induced to have either KSTA or 
Lyme arthritis.  Inflammatory indices were generated as described (300) for 
both the KSTA and Lyme arthritis models.  Quantities of pro- or anti-inflammatory 
metabolites upregulated by a fold change of two or more were calculated in the 
KSTA model on days 0, 3, 7, 14, 17, and 21 post-serum transfer and in the Lyme 
arthritis model on days 0, 3, 7, 10, 14, 17, 21, 24, 28 and 35 post-infection.  n = 5 
on day 0, 9 on day 3 and 14, 10 on day 7 and 21, and 8 on day 17 post-serum 
transfer in the KSTA model, and n = 5 for every time point in the Lyme arthritis 
model.  Data represents the percentage of metabolites upregulated at each time 
point.  (A) pro- and anti-inflammatory metabolite generation throughout the KSTA 
model,  (B) pro-inflammatory metabolite production in the KSTA and Lyme 
arthritis models, and (C) anti-inflammatory metabolite production in the KSTA 
and Lyme arthritis models.  (Eicosanoids were detected by Dr. Darren S. Dumlao 
using LC-MS/MS, inflammatory indices and figures were calculated and 
generated by Anna M. Cunningham.) 
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suggests that the percentage of pro-inflammatory and anti-inflammatory 
metabolites were equivalent in control mice and on days 3 and 7 post-serum 
transfer; however, on days 14,17, and 21 post-serum transfer, the percentage of 
pro-inflammatory metabolites was larger than the percentage of anti-
inflammatory metabolites.  This data suggested that early during disease, anti-
inflammatory metabolites were produced in an effort to limit inflammation induced 
by potent inflammatory metabolites.  This data may also suggest that the 
production of anti-inflammatory metabolites early during disease was important 
for subsequent resolution (7, 299).  However, the predominance of pro-
inflammatory metabolites at times during which inflammation was decreasing 
(fig. 6.1) is perplexing.  A possible explanation for this observation is that the 
function of many of these metabolites varies depending on microenvironment 
and cellular composition.  For example, PGE2 has been implicated to be pro-
inflammatory when produced in low quantities and anti-inflammatory when 
produced in high quantities (60, 301).  The function of PGE2 may also vary 
depending on cellular composition of the joint, as four receptors for PGE2 exist 
(EP1 – EP4) and are differentially expressed on distinct cell types (302).  As the 
predominance of cells in joint tissue shifts from neutrophils during the peak of 
arthritis to macrophages during resolution (fig. 6.1 D), an alteration in eicosanoid 
receptor expression in the joint could affect the function of these eicosanoids. 
 To compare the production of lipid mediators in this model of arthritis to 
those produced in another well-established model, we calculated inflammatory 
indices from the lipidomic data that we accumulated using the Lyme arthritis 
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model (144) (fig. 6.10 B, C).  We found that the production of pro-inflammatory 
mediators was much higher in KSTA when compared to Lyme arthritis  (fig. 6.10 
B) and that the production of anti-inflammatory mediators was higher in Lyme 
arthritis (fig. 6.10 C).  Inflammation resulting from Lyme arthritis does not reach 
the severity that is seen in KSTA, which may explain why pro-inflammatory 
indices for KSTA are much higher than those found in Lyme arthritis (fig. 6.10 B).  
Furthermore, Lyme arthritis is a transient arthritis that requires lipid mediators for 
the resolution of arthritis (141, 142), while resolution of KSTA correlates with the 
degradation of passaged anti-GPI autoantibodies.  Thus, the higher anti-
inflammatory index found in Lyme arthritis may be explained by the greater role 
that these mediators play in the cessation of inflammation in this model (fig. 6.10 
C). 
 
III. DISCUSSION 
 The K/BxN serum transfer model of arthritis (KSTA) has proven to be a 
beneficial model for the study of human rheumatoid arthritis due to many shared 
symptoms and pathways mediating disease (252, 253).  Eicosanoids are known 
to interact with immune pathways that mediate KSTA (109, 110, 259, 263).  
Previous data has implicated a role for the enzymatic pathways 5-lipoxygenase 
(5-LOX) and cyclooxygenase-1 (COX-1) and their respective products, 
leukotriene B4 (LTB4) and prostaglandin I2 (PGI2), in the generation and 
maintenance of arthritis resulting from the transfer of anti-glucose-6-phosphate 
isomerase (GPI) autoantibody-containing K/BxN serum (109, 259).   
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 To better understand which eicosanoid pathways were engaged during 
KSTA, we utilized a methodology we developed that uses liquid chromatography-
tandem mass spectrometry to temporally identify eicosanoids directly from 
arthritic tissues (144).   
 Using this methodology, we identified that the peak of eicosanoid 
generation during KSTA is day 7 (fig 6.3 B), correlating with the peak of arthritis 
severity (fig. 6.1).  We found that the most commonly utilized eicosanoid 
enzymatic pathway was the cytochrome P450 (CYP) pathway (fig. 6.3 A).  This 
pathway produces the vasoactive HETEs and EETs.  Vasodilatory EETs were 
expressed to higher levels than the vasoconstrictive HETEs (fig. 6.4, 6.5), 
suggesting that the overall vascular tone during the peak of arthritis was 
conducive to vascular leakage and the infiltration of immune cells, thus promoting 
inflammation. 
 Non-enzymatically-produced metabolites were also dynamically regulated 
throughout the course of KSTA (fig. 6.3 A, fig. 6.6), suggesting that the joints of 
arthritic mice consist of a highly oxidative microenvironment that likely contribute 
to the severity of inflammation.  This is consistent with studies indicating that 
molecules that limit restrain oxidative stress, such as heme-oxygenase 1 (HO-1), 
are important for limiting severity of KSTA disease (283). 
 The production of LTB4 was elevated throughout the course of KSTA (fig. 
6.8 A), which is consistent with data indicating that this molecule mediates the 
recruitment of neutrophils and stimulation of fibroblast-like synoviocytes (FLS) at 
numerous stages of this disease.  The production of PGF1α, the breakdown 
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product of PGI2, was elevated on days 7 and 21 post-serum transfer (fig. 6.7 A).  
As PGI2 is known to regulate the development of disease in this model, the 
production of PGF1α at the peak of disease, day 7, makes sense.  However, the 
reason for its production at day 21, a time point at which arthritis has been 
resolved, is less clear.  Studies have indicated that the production of PGI2 is 
stimulated by IL-6 produced subsequent to IL-1β stimulation of synovial 
fibroblasts (290).  The development of KSTA is mediated by a cascade of 
neutrophil recruitment, mediated in part by LTB4 and IL-1β, resulting in the 
proliferation of invasive and destructive FLS (110, 261).  C5a stimulation of the 
“first wave” of LTB4-producing neutrophils leads to the recruitment of immune 
complex-stimulated, IL-1β-producing neutrophils (261).  Although the production 
of PGF1α was detected at day 21 post-serum transfer, this molecule is a 
breakdown product of PGI2 and thus could indicate that PGI2 was being 
produced at slightly earlier time points.  Furthermore, the occurrence of this 
molecule late in disease may corroborate data that suggests that neutrophils 
produced later in disease (the “second” wave of IL-1β-producing neutrophils) are 
important for the induction of disease-modulating PGI2. 
 Although previous data suggests that COX-2 does not play a role in 
modulating KSTA (259), we detected high levels of metabolites produced via this 
pathway (fig. 6.7 D, E).  We have previously shown that COX-2 mediates the 
resolution of Lyme arthritis (141).  It is possible that anti-inflammatory COX-2 
metabolites are produced at the peak of KSTA in an effort to induce resolution of 
arthritis.  However, due to the fact that the resolution of KSTA is mediated by the 
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degradation of passaged autoantibodies, it is unlikely that any effects would be 
seen in the absence of COX-2.  Thus, the role of COX-2-derived metabolites in 
the regulation of KSTA remains somewhat unclear. 
 We have previously conducted a similar study utilizing the same lipidomics 
methodology to detect the production of eicosanoids throughout the course of 
Lyme arthritis (144).  In the Lyme arthritis study, similar to the present study, we 
found that the majority of eicosanoids were produced at the peak of disease, day 
10 post-infection.  Interestingly, all eicosanoids were produced at much higher 
levels in joints of mice induced to have KSTA when compared to mice with Lyme 
arthritis.  In an effort to better understand this discovery, we generated pro- and 
anti-inflammatory scores by calculating the percentage of metabolites that were 
affected by a fold change of 2 or more with known pro- or anti-inflammatory 
functions (300) (fig. 6.10).  Pro-inflammatory metabolites were produced at much 
higher levels in the joints of mice with KSTA while the joints of mice with Lyme 
arthritis tended to produce more anti-inflammatory metabolites (fig. 6.10 B, C).  
This data emphasizes the fact that inflammation resulting from KSTA is much 
more severe than inflammation resulting from Lyme arthritis (compare severity 
reported in Blaho, et al. 2009 (144) and fig. 6.1), but also highlights the fact that 
pro-resolving metabolites are necessary for resolution of Lyme arthritis but 
dispensable for the resolution of KSTA.  The increased severity in this model is 
likely responsible for the increased expression of eicosanoids measured in this 
study. 
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 The data presented herein is consistent with studies indicating that COX-
1-derived PGI2 and 5-LOX-derived LTB4 are involved in disease associated with 
KSTA.  Furthermore, our data suggests that pathways that regulate vascular tone 
(CYP) and oxidative stress (non-enzymatic) are heavily involved in the 
development of this disease.  The methodology used to obtain these results is a 
useful tool for the identification of pathways and metabolites that regulate 
inflammation resulting from various forms of disease.  These results emphasize 
the fact that eicosanoids are dynamically regulated throughout the course of 
arthritis and are important mediators of inflammation.  
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CHAPTER SEVEN 
 
CONCLUSIONS 
 
 Lyme disease was first described by Steere, et al. in 1977 after an 
outbreak of an apparent juvenile rheumatic disease in Lyme, Connecticut (122, 
303-306).  Epidemiological data suggested transmission of the disease occurred 
via tick vector, specifically via the Ixodes species of ticks (the black-legged deer 
tick, Ixodes scapularis) (307).  It was not until1982 that the causative spirochete 
was isolated from an Ixodes tick and named for its discoverer, Dr. Willy 
Burgdorfer: Borrelia burgdorferi (Bb) (123).   
 Early clinical manifestations of human Lyme disease include mild flu-like 
symptoms and a bull’s eye-shaped rash termed erythema migrans (EM).  Later 
stage symptoms include arthritis of the large joints and carditis (124).  In 1990, 
CD-1 mice were identified as a beneficial animal model with which to study Lyme 
disease as inoculation with Bb resulted in disease that was comparable to that 
observed in humans: severe arthritis and carditis (308). 
 It was observed early on that a genetic component determining 
susceptibility to murine Lyme disease existed.  In 1990, Barthold, et al. surveyed 
five strains of mice and determined that while all mice were susceptible to 
infection with Bb, only two out of the five strains developed severe arthritis 
following inoculation with Bb [C3H/He (C3H) and SWR] and the other three 
strains remained resistant to disease [C57BL/6 (B6), BALB/c, and SJL] (130).  
Using C3H and B6 mice with or without the beige (bg) mutation, which impairs 
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granulocyte and NK cell function, Barthold et al. determined that genetic 
susceptibility to murine Lyme arthritis was likely linked to granulocyte function 
(309).   
 In 2003, Brown et al. discovered that the chemokines KC and MCP-1 were 
upregulated in genetically susceptible C3H mice compared to resistant B6 mice 
(132).  While C3H mice deficient in CCR2, the receptor for MCP-1, remained 
susceptible to disease following inoculation with Bb, C3H mice deficient in the 
chemokine receptor CXCR2 were resistant to disease.  In the study described in 
chapter three of this thesis, C3H KC-/- mice were used to determine definitively 
that the chemokine KC signaling through CXCR2 is responsible for neutrophil 
recruitment and subsequent development of both arthritis and carditis following 
inoculation with Bb.  Furthermore, the CXCR2 ligands MIP-2 and LIX were 
unable to compensate for the loss of KC signaling through CXCR2.  These 
studies were the first to determine an immunological regulatory mechanism 
mediating disease susceptibility to murine Lyme disease.  Future studies would 
do well to determine potential genetic mechanisms that regulate KC transcription 
and translation, as these may aid in the determination of genetic factors that 
mediate murine susceptibility or resistance to Lyme disease.  As p38 mitogen 
activated protein kinase (p38 MAPK) is known to mediate the production of pro-
inflammatory cytokines in response to Bb (likely including KC) (140), further 
investigation of differences in this pathway may aid in the clarification of why B6 
mice produce so much less KC compared to C3H mice and thus further elucidate 
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mechanisms responsible for determining genetic susceptibility or resistance to 
murine Lyme disease. 
 Although genetic factors regulate the susceptibility or resistance of mice to 
Lyme disease, many other factors are known to mediate the severity of disease 
in susceptible mice.  One such group of factors is the small, immuno-regulatory 
eicosanoids (310).  In 2009, Blaho et al. isolated lipids directly from the ankle 
joints of Bb-infected mice and used lipidomics to show dynamic expression of 
eicosanoids throughout the course of disease (144).  Pro-inflammatory 
prostaglandins and leukotrienes were produced in the early stages of Lyme 
arthritis and pro-resolving molecules (such as protectin D1) were produced at the 
peak of arthritis severity, likely in an effort to promote resolution. 
 Studies using mice genetically deficient in eicosanoid biosynthetic 
enzymes such as 5-LOX-/-, COX-1-/-, and COX-2-/- have determined that these 
pathways are important for the regulation of various aspects of the immune 
response to Bb.  5-LOX is responsible for the production of pro-inflammatory 
leukotrienes, but is also required for the production of the anti-inflammatory/pro-
resolving lipoxins, protectins, and resolvins.  Mice deficient in 5-LOX were able to 
mount an effective immune response to Bb and developed arthritis normally, but 
were unable to resolve arthritic inflammation, suggesting that 5-LOX deficiency 
results in defective pro-resolution mechanisms (142).  COX-1-/- mice had no 
noticeable defect in the ability to develop or resolve arthritic inflammation in 
response to Bb, but were unable to form functional germinal centers and produce 
IL-6 and IL-17 (143). 
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 Inhibition of the enzyme COX-2 resulted in attenuated arthritis severity 
and the development chronic arthritis, suggesting that metabolites produced via 
this pathway are responsible for both pro-inflammatory and pro-resolution 
mechanisms (141).  Lipidomic analysis of COX-2-/- mice revealed that 
interference with this pathway also negatively impacts the production of 
lipoxygenase metabolites, indicating that defects in the pro- and anti-
inflammatory machinery resulting from COX-2 inhibition could be due to 
decreased prostaglandin, leukotriene, lipoxin, protectin, and/or resolvin 
production (144). 
 In chapter six of this thesis, lipid and cytokine analysis was performed in 
order to further elucidate the global effects of COX-2 inhibition.  Interestingly, 
results from this study varied from those previously described by Blaho, et al.  
Blaho, et al. observed that mice treated with the COX-2 inhibitor Celecoxib 
developed persistent arthritis that was unable to resolve by day 35 post-infection 
(141).  In the study presented herein, mice treated with Celecoxib had fully 
resolved arthritis by day 62 post-infection.  This data suggests the possibility that 
COX-2 inhibition does not prevent resolution, but rather delays it significantly.  As 
the study explained in chapter six involved feeding mice Celecoxib for two weeks 
prior to infection with Bb and Blaho et al. only fed mice Celecoxib starting on day 
-1 prior to Bb infection, it is also possible that such an extended time of COX-2 
inhibition resulted in the development of compensatory mechanisms altering the 
outcome of the experiment.  However, the latter explanation is unlikely, as 
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studies exploring COX-2 inhibition to date have not identified any functional 
compensatory mechanisms. 
 Of the several metabolites produced via the COX-2 pathway, perhaps the 
best recognized is PGE2.  In the context of inflammation, PGE2 has classically 
been considered pro-inflammatory due to its ability to stimulate tissue edema and 
cytokine production (206).  However, recent studies have determined that PGE2 
may actually function as a “switch” that mediates the shift from pro-inflammatory 
to pro-resolving metabolites (82).  It is possible, then, that the absence of PGE2 
signaling during COX-2 deficiency or inhibition is responsible for the lack of Lyme 
arthritis resolution.  PGE2 has 4 difference receptors (EP1, 2, 3, and 4).  EP2 and 
EP4 have been implicated the most for arthritic inflammation.  In chapter six, we 
treated COX-2-/- mice with Butaprost, an agonist of the EP2 receptor, and found 
that this treatment restored resolution in the COX-2-/- mice.  This data suggested 
that defective resolution observed during COX-2 inhibition or deficiency results 
from a lack of PGE2 signaling through the EP2 receptor.  Future studies would 
benefit from further exploring the role PGE2 plays in Lyme arthritis and 
mechanisms by which it may induce pro-resolution mechanisms such as the 
production of lipoxin. 
 The majority of eicosanoids studied in the context of inflammation are 
derived from the ω-6 fatty acids (2-series prostaglandins and 4-series 
leukotrienes derived from linoleic and arachidonic acid).  Metabolism of ω-3 fatty 
acids (EPA and DHA) results in the production of the 3-series prostaglandins and 
5-series leukotrienes.  ω-3-derived eicosanoids are much less bioactive than 
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their ω-6-derived counterparts and recent data has suggested that dietary 
supplementation with ω-3 fatty acids (via consumption of fish oil) may be useful 
for the alleviation of immune disorders.  Studies have shown that ω-3 
supplementation may be beneficial for the mitigation of symptoms associated 
with diabetes, cystic fibrosis, cardiovascular disease, cancer, and rheumatoid 
arthritis (81, 210-214), although the mechanisms by which fish oil/ω-3 fatty acids 
mediate these anti-inflammatory effects are poorly understood. 
 In chapter four of this thesis, mice were fed a diet in which the fatty acid 
source was fish oil (compared to the control diet, in which the fatty acid source 
was soy oil) and eicosanoid production was assessed throughout the course of 
Lyme arthritis.  A previous study using a murine model of influenza observed that 
dietary fish oil supplementation resulted in attenuated lung inflammation, but 
increased mortality due to significantly increased viral titers in the lung (311).  
Therefore, the predicted outcome of the study in chapter four was that arthritis 
severity would be reduced in mice fed the fish oil diet and that these mice would 
have higher Bb titers.  As the enzymes responsible for eicosanoid production 
would be utilizing the supposedly more anti-inflammatory ω-3 fatty acid as 
substrates, it was hypothesized that the production of eicosanoids would be 
skewed toward anti-inflammatory/pro-resolving metabolites. 
 Rather than a skewing of pro- to anti-inflammatory metabolites, a global 
shift in eicosanoid production was observed in the fish-oil fed mice where the 
vast majority of eicosanoids were derived from ω-3 fatty acids.  Although this 
would perhaps lead one to suspect that disease would be attenuated in these 
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mice, this was not the case.  Fish oil-fed mice and control diet-fed mice had 
similar disease and Bb titers.  This suggested that although fish oil may lead to 
attenuated inflammation in some models, it is not a sufficient anti-inflammatory 
for Lyme arthritis.  It is important to note, however, that the quantity of fish oil that 
was included in the experimental diet far exceeds what is possible for human 
dietary supplementation.  Therefore, it is possible that a threshold exists 
determining the therapeutically effectiveness of fish oil and that threshold was 
exceeded in this experiment. 
 Interestingly, although the vast majority of eicosanoids produced in the 
ankle joints of fish oil-fed mice were of ω-3 origin, one ω-6-derived eicosanoid 
was increased compared to control diet-fed mice: the PGD2 dehydration product 
15d-PGJ2.  As previously mentioned, this metabolite is considered anti-
inflammatory due to its inhibitory effects on NF-κB.  Expression of this metabolite 
in the fish oil-fed mice reached levels at which PGE2 was produced in the control 
diet-fed mice.  Upon further analysis, it was determined that fish oil-fed mice 
accumulated higher levels of PGD2-related products than PGE2-related products.  
This data suggests that fish oil could potentially exert anti-inflammatory activity 
via altered prostaglandin synthase activity.  While soy oil results in the 
preferential production of PGE synthase products, fish oil results in the 
preferential production of PGD synthase products.  Further investigation of the 
effects of ω-3 fatty acids on prostaglandin synthase usage could potentially 
identify novel anti-inflammatory mechanisms of dietary fish oil supplementation. 
156 
 Human arthritis is a grouping of over 100 disorders characterized by joint 
inflammation, pain, stiffness, and swelling.  As the instigating source of joint 
inflammation is typically unknown, treatments for most arthritides focus on 
managing pain and reducing symptoms to allow patients to carry on with normal 
life.  Non-steroidal anti-inflammatory drugs (NSAIDs) have been extensively used 
in the management of pain and inflammation associated with arthritis.  NSAIDs 
function by inhibiting pathways responsible for eicosanoid generation.   
 As described in chapter six, it is well established that eicosanoids play a 
role in the pathogenesis of Lyme arthritis and inhibition of eicosanoid biosynthetic 
pathways results in altered disease states upon infection with Bb.  However, 
inhibition of these pathways in other models of arthritis does not result in the 
same effects.  In chapter five, the production of eicosanoids during a different 
model of arthritis, K/BxN serum transfer arthritis (KSTA), was assessed.  This 
model of arthritis is autoimmune in nature.  Its development is reliant on the 
passage of autoantibodies and its cessation correlates with the natural 
degradation of these autoantibodies.  While deficiency of COX-1 during Lyme 
arthritis has no discernable effect on arthritis development or resolution, COX-1 
deficiency during KSTA results in attenuated disease (259).  Furthermore, while 
5-LOX deficiency during Lyme arthritis has not effect on the development of 
arthritis, resolution in these mice is defective.  However, development of KSTA is 
dependent on the 5-LOX metabolite LTB4 signaling through its cognate receptors 
BLT-1 and BLT-2 (109). 
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 Global eicosanoid production in the ankle joints of mice induced to have 
KSTA was compared to ankle joint eicosanoid production during Lyme arthritis.  
Pro-inflammatory mediators were produced in greater quantities during KSTA 
compared to Lyme arthritis, which most likely represented the fact that joint 
inflammation is much more severe in the model of KSTA.  It was also observed 
that anti-inflammatory metabolites were produced in higher quantities during 
Lyme arthritis than KSTA.  As Lyme arthritis requires active resolution while 
resolution of KSTA is associated with the passive degradation of transferred 
autoantibodies, the higher quantities of anti-inflammatory metabolites produced 
in Lyme arthritis may indicate the greater need for them for the induction of 
resolution in this model. 
 The differences observed in the model of Lyme arthritis and KSTA 
highlight an important caveat to arthritis research: not all arthritides are the same.  
As mentioned previously, arthritis is actually the collection of 100 different 
disorders with similar symptoms.  In order to translate laboratory findings to 
human medicine and potential therapeutics for various disorders, it is vital to use 
numerous animal models.  
 The studies contained in this thesis contribute greatly to the understanding 
of Lyme arthritis pathogenesis.  From the elucidation of chemokine pathways 
responsible for the development of Lyme arthritis to the appreciation of the many 
ways which eicosanoids regulate disease in this model, the work presented 
herein serves as a strong foundation for future studies to be built upon.  Further 
understanding of the pathogenesis of murine Lyme arthritis will aid in the 
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development of more sophisticated therapeutics that can be used for the 
treatment of human Lyme arthritis and other forms of arthritis, as well. 
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